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Abstract 
Autosomal dominant optic atrophy (DOA) classically presents with bilateral, 
symmetric visual failure in early childhood, with the pathological hallmark being the 
selective loss of retinal ganglion cells (RGCs). In the first population-based 
epidemiological study of DOA, we were able to estimate its minimum prevalence at 1 
in 35,000 in the North of England. In independent case series from Northern Europe 
and North America, the majority of families with DOA harboured pathogenic OPA1 
mutations (50.0-57.6%), and large-scale OPA1 rearrangements were present in only a 
small subgroup (11.1-12.9%). We also confirmed that OPA3 mutations were very rare 
in non-syndromal DOA cases. Visual deterioration was observed in over half (54.2-
67.4%) of all patients during long term follow-up, and the rate of visual decline varied 
markedly both between and within families. 
In a large multi-centre study of 104 OPA1-positive patients from 45 independent 
families, we established that additional neuromuscular complications are common in 
OPA1 disease, affecting up to 20% of all mutational carriers. Bilateral sensorineural 
deafness beginning in late childhood and early adulthood was a prominent 
manifestation, followed by a combination of ataxia, myopathy, peripheral neuropathy 
and chronic progressive external ophthalmoplegia (CPEO) from the third decade of life 
onwards. We also identified novel clinical presentations with spastic paraparesis 
mimicking hereditary spastic paraplegia, and a multiple sclerosis-like illness. Patients 
with these syndromal disease variants (DOA+) had a worse visual prognosis, and this 
was associated with a more pronounced reduction in retinal nerve fibre layer thickness 
compared to patients with pure DOA. Interestingly, there was a two- to three-fold 
 
X 
increased risk of developing DOA+ features with missense OPA1 mutations and those 
located within the GTPase domain. 
The molecular investigations of our DOA families have confirmed that OPA1 
mutations result in mitochondrial DNA (mtDNA) instability, with the accumulation of 
multiple mtDNA deletions causing cytochrome c oxidase (COX)-deficiency. The 
frequency of COX-negative fibres in skeletal muscle biopsies was over four times 
higher in the DOA+ group compared to the pure optic atrophy group. Importantly, 
COX-negative muscle fibres were also more frequent among patients with pure DOA 
compared to age-matched healthy controls. These observations clearly implicate a 
contributory role for these secondary mtDNA defects in triggering multi-system 
cellular dysfunction among affected OPA1 carriers. Using a real-time, quantitative 
polymerase chain reaction assay, we subsequently found that patients with DOA+ 
features had significantly greater mtDNA proliferation in their COX-negative skeletal 
muscle fibres compared to patients with isolated optic neuropathy. Low levels of wild-
type mtDNA molecules were present in COX-negative muscle fibres from both pure 
DOA and DOA+ patients, implicating haploinsufficiency as the mechanism 
responsible for the biochemical COX defect. 
Although the accumulation of somatic, clonally-expanded mtDNA deletions is likely to 
be a key pathological player in DOA, we found no evidence of COX-deficiency or 
multiple mtDNA deletions in post-mitotic tissues from two Opa1 mouse models. These 
results are not surprising as OPA1 mutations are likely to exert other deleterious 
consequences at the cellular level. To explore these disease mechanisms further, we 
used in vivo phosphorus magnetic resonance spectroscopy (
31
P-MRS) to specifically 
measure mitochondrial oxidative function in 17 OPA1-positive patients manifesting 
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both pure DOA (N = 9) and DOA+ phenotypes (N = 8). OPA1 mutations impaired 
mitochondrial oxidative phosphorylation, but there was no significant difference in 
31
P-
MRS parameters between these two OPA1 disease subgroups. Our observations clearly 
suggest that additional factors must be contributing to RGC loss and cellular 
dysfunction in other organ systems. 
Primary open angle glaucoma is a progressive optic neuropathy characterised by the 
selective loss of RGCs, pathological optic disc cupping, and visual field defects. It has 
a major genetic basis and it shares striking clinical and pathological overlap with DOA. 
Since the OPA1 protein is closely linked with normal RGC function, we investigated 
whether OPA1 single nucleotide polymorphisms (SNPs) influenced the risk of 
developing glaucoma. We found a strong association between two specific OPA1 
SNPs (IVS8+4c>t and IVS8+32t>c) and the risk of developing normal tension 
glaucoma, but not high tension glaucoma. These findings support a possible role for 
the OPA1 protein in the pathophysiology of normal tension glaucoma. 
Leber hereditary optic neuropathy (LHON), with DOA, are the two most common 
inherited optic neuropathies seen in clinical practice. Over 90% of LHON cases are 
due to one of three primary mtDNA mutations: m.3460G>A (MTND1), m.11778G>A 
(MTND4), and m.14484T>C (MTND6). Visual loss in LHON is usually severe with 
little functional improvement. Using the Visual Function Index (VF-14) questionnaire, 
qualify of life among LHON carriers was quantified for the first time. LHON had the 
worst VF-14 score when compared to other acquired and inherited ophthalmological 
disorders, highlighting the significant visual impairment caused by this disorder. 
Patients with the m.14484T>C mutation had higher VF-14 scores compared with those 
harboring the m.3460G>A and m.11778T>C mutations, which is consistent with 
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previous observations that this primary mutation carries a better prognosis for visual 
recovery. LHON is a complex disease, and we systematically explored the role of 
potential environmental triggers in a large cohort of 196 affected and 206 unaffected 
carriers (N = 402) from 125 Northern European LHON pedigrees. We found a strong 
and consistent association between visual loss and smoking, with heavy smokers being 
more likely to be affected than light smokers. There was also a trend towards an 
increased risk of visual failure with alcohol, but only among heavy drinkers. Based on 
our results, asymptomatic LHON carriers should be strongly advised not to smoke and 
to moderate their alcohol intake. 
Extraocular muscles (EOMs) are frequently involved in patients with mitochondrial 
genetic disorders and it is often the major cause of morbidity. In order to explore this 
selective vulnerability, we studied the mitochondrial changes seen in EOMs as part of 
the normal ageing process. COX-negative fibres were seen in EOMs from the third 
decade of life, and in the majority of these fibres (72.5%), mtDNA deletions were 
detected at levels over 70%. An exponential, age-related increase in COX-deficiency 
was observed in EOMs, and this occurred at a faster rate than skeletal muscle. In a 
parallel study, we investigated EOM and skeletal muscle biopsies from 13 patients 
with confirmed CPEO. We found significantly higher levels of COX-negative fibres in 
EOMs (41.6%) compared to skeletal muscle (13.7%), and this difference was linked to 
a lower mutational threshold for COX deficiency in EOMs. Because of their intrinsic 
biological properties, EOM fibres accumulate mtDNA deletions and COX deficiency 
at an accelerated rate as part of normal ageing. In the presence of an underlying 
mtDNA defect, this greater susceptibility is accentuated further, resulting in the 
prominent and often restricted EOM involvement seen in patients with CPEO. 
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Introduction 
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1.1 The Mitochondrion 
1.1.1 Evolutionary Origin 
Mitochondria are ubiquitous intracellular organelles and they fulfil a fundamental  role 
by providing most of the adenosine triphosphate (ATP) requirements of eukaryotic 
cells (DiMauro and Schon, 2003). The prevailing endosymbiotic hypothesis suggests 
that mitochondria evolved from aerobic α-proteobacteria, which were then gradually 
assimilated by primitive glycolytic eubacteria (Margulis, 1971; Gray et al., 1999). 
During evolution, the α-proteobacteria gradually transferred the majority of their 
genetic material to the eubacteria‟s nuclear chromosomes, resulting in a symbiotic 
relationship (Gabaldon and Huynen, 2004). Phylogenetic comparison of mitochondrial 
DNA (mtDNA) between modern humans and other organisms, including Rickettsia 
prowazekii, an α-proteobacterium, support this common evolutionary origin for the 
mitochondrial genome (Martin and Muller, 1998; Gray et al., 1999). 
1.1.2 Mitochondrial Structure 
Mitochondria are tubular-shaped organelles bounded by an outer and an inner 
membrane, and these delineate two distinct compartments: an intermembrane space 
and an internal matrix space (Figure 1) (Alberts et al., 1994; Frey and Mannella, 
2000). The outer membrane allows passive diffusion of low molecular weight 
molecules up to 10 kDa, and this permeability is conferred by a family of channel-
forming proteins known as porins, or voltage dependent anion channels (VDAC). The 
inner membrane is highly convoluted and these multiple infoldings, known as cristae, 
greatly increase its effective surface area (Perkins et al., 1997). Compared to the outer 
membrane, the inner membrane is relatively impermeable except for specific active  
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Figure 1. The major structural features of a mitochondrion: (A) Schematic 
representation, (B) Transmission electron micrograph. Reproduced from 
Alberts et al (1994). 
 
transport channels, allowing an electrochemical gradient to be established across this 
barrier. The inner membrane also contains a number of highly specialised proteins, 
including the respiratory chain complexes and members of the mitochondrial 
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membrane protease family. The mitochondrial matrix compartment contains mtDNA 
molecules within nucleoid structures, and it is also the site of multiple metabolic 
pathways essential for normal cellular function: the citric acid cycle, -oxidation of 
fatty acids, steroid, and amino acid biosynthesis (Raha and Robinson, 2000). 
1.1.3 Oxidative Phosphorylation 
The mitochondrial respiratory chain comprises five multi-subunit polypeptide 
complexes (I-V) which are embedded within the inner mitochondrial membrane 
(Figure 2) (Nijtmans et al., 2004). The production of ATP is tightly regulated and it is 
the end-product of a process known as oxidative phosphorylation (OXPHOS). Acetyl-
CoA, an intermediate product of glycolysis and -oxidation, is metabolised further by 
the citric acid cycle to the reducing equivalents nicotinamide adenine dinucleotide 
hydrogen (NADH) and flavin adenine dinucleotide hydrogen (FADH2) (DiMauro and 
Schon, 2003). NADH and FADH2 are then re-oxidised by donating electrons to 
complexes I and II respectively. The energy released by the shuttling of these high 
energy electrons along the respiratory chain complexes allows protons to be pumped 
from the matrix compartment into the intermembrane space. Two additional carriers, 
ubiquinone (Coenzyme Q10) and cytochrome c, also play critical roles in the efficient 
transfer of electrons through these successive oxidation-reduction reactions. The 
electrochemical gradient generated across the inner mitochondrial membrane is then 
used  by complex V (ATP synthase) to catalyze the conversion of adenosine 
diphosphate (ADP) and inorganic phosphate (Pi) to ATP. 
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1.1.3.1 Complex I 
Complex I (NADH-ubiquinone oxidoreductase) is an L-shaped  molecule with two 
arms, one in the same plane as the inner mitochondrial membrane, and the other 
projecting into the mitochondrial matrix (Grigorieff, 1999; Hirst et al., 2003). It is the 
largest respiratory chain complex, with a total molecular mass of 980 kDa, and it 
consists of ~ 46 subunits, seven of which are mitochondrially-encoded (Table 1). 
Complex I contains the co-enzyme flavin mononucleotide (FMN) and eight iron-
sulphur complexes involved in the electron transfer process (Koopman et al., 2007). 
 
 
Figure 2. The mitochondrial respiratory chain and oxidative phosphorylation. 
Reproduced from Nijtmans et al (2004). 
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1.1.3.2 Complex II 
Complex II (Succinate-ubiquinone oxidoreductase) has unique features which 
distinguish it from the other respiratory chain complexes. It is not a proton pump and it 
consists of four subunits (A-D), which are all nuclear-encoded (Hatefi and Galante, 
1980; Yue et al., 1991). Complex II is the smallest respiratory chain complex, with 
subunits A (73kDa) and  B (27kDa) located on the matrix side, and two smaller 
hydrophobic subunits, C and D, acting as anchoring membrane proteins (Lancaster and 
Kroger, 2000). Complex II contains various prosthetic groups: a covalently-bound 
flavin adenine dinucleotide (FAD) coenzyme (Subunit A), three iron-sulphur centres 
(Subunit B), and haem groups (Subunits C and D). 
1.1.3.3 Complex III 
Complex III (Ubiquinol-cytochrome c oxidoreductase) has a dimeric structure with a 
molecular weight of 480 kDa (Acin-Perez et al., 2004). Each monomer has 11 different 
polypeptide subunits, of which only one is mitochondrially-encoded (Cytochrome b). It 
contains various active redox prosthetic groups: cytochrome b which contains two 
haem groups, cytochrome c1, and iron-sulphur clusters (Rieske protein), which 
assemble into a functional structure known as the cytochrome bc1 complex (Yu et al., 
1999). 
1.1.3.4 Complex IV 
Complex IV (Cytochrome c oxidase) has 13 subunits, and three of these subunits are 
encoded by the mitochondrial genome (Kadenbach et al., 1983; Tsukihara et al., 1996). 
It is a water soluble haemoprotein complex, 204 kDa in size, containing two non-
covalently bound haem groups (Cytochromes a and a3), and two copper centres (CuA 
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and CuB). Complex IV acts as the terminal electron acceptor, with cytochrome a3 and 
CuB forming a binuclear centre for oxygen reduction. These catalytic sites bind oxygen 
in a reaction which utilises four electrons, resulting in four substrate protons being 
converted to two molecules of water (Faxen et al., 2005). 
1.1.3.5 Complex V 
Complex V (ATP synthase) has an approximate molecular mass of 500 kDa, and it is 
made up of 16 different subunits, two of which are mitochondrially-encoded (von 
Ballmoos et al., 2009). These subunits assemble into two main structural units: Fo 
which is embedded in the inner mitochondrial membrane, and the catalytic domain F1 
which is located in the matrix compartment. F1 is composed of 5 different subunits α, 
β, γ, δ and ε, with three α and three β subunits arranged alternately to form a cylinder 
(αβ)3 around γ (Abrahams et al., 1994; Yoshida et al., 2001). The Fo structure has an 
a1b2c12 stoichometry, with a cylindrical arrangement of c subunits bounded 
peripherally by subunits a and b. The subunit c ring is also linked to the γ subunit of 
the F1 core both directly, and indirectly through mutual contacts with the ε subunit. The 
current working model of ATP synthase is based on a rotor-stator mechanism, with the 
rotor consisting of a c12 oligomer, and the stator arm being formed by an ab2 complex 
and subunit δ (Gibbons et al., 2000; Ko et al., 2000). The translocation of protons by 
complexes I, III and IV creates an electrochemical gradient across the inner 
mitochondrial membrane, and this proton motive force is used to generate Fo rotatory 
movements. The generated torque alters the conformational states of the β subunits, via 
the rotor and stator, eventually resulting in the synthesis of ATP molecules within F1 
(Yoshida et al., 2001). 
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Table 1. The constituent subunits of the mitochondrial respiratory chain 
complexes. 
Respiratory Chain Complex 
Gene Location 
MtDNA Nuclear DNA 
        Complex I 7 ~ 39 
        Complex II 0 4 
        Complex III 1 10 
        Complex IV 3 10 
        Complex V 2 14 
 
1.2 Mitochondrial Genetics 
1.2.1 Mitochondrial DNA 
Mitochondria are unique in having their own genome in the form of a circular, double-
stranded molecule 16,569 base pairs long (Figure 3) (Anderson et al., 1981; Andrews 
et al., 1999; Strachan and Read, 1999). It is a high-copy genome, with 2-10 mtDNA 
molecules in each mitochondrion, and hundreds to thousands of mitochondria per cell 
depending on their specific energy requirements (Chinnery et al., 1999a; Kirkman et 
al., 2008). MtDNA replicates continuously and this process is independent of the 
nuclear genome, occurring in both mitotic and post-mitotic cells. The mitochondrial 
genome codes for 2 ribosomal RNAs (12S and 16S rRNA), 22 transfer RNAs (tRNAs), 
and 13 polypeptide subunits of the respiratory chain complexes (Taylor and Turnbull, 
2005). The majority of these genes are located on the H-strand, with only MTND6 and 
eight tRNA genes found on the L-strand. MtDNA is a very compact molecule, with 
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overlapping gene regions, and the absence of introns. As a result of these distinct 
characteristics, tRNA genes often act as punctuation markers during the processing of 
polycistronic mRNA transcripts (Ojala et al., 1980b; Montoya et al., 1981; Ojala et al., 
1981). However, the mitochondrial genome does contain a non-coding region, known 
as the D-loop, which is involved in mtDNA transcription and replication. This 1.1 Kb 
region also contains the regulatory elements for mtDNA expression, with binding sites 
for mitochondrial transcription factor A (TFAM), three conserved sequence blocks 
(CSB), and a termination associated sequence (TAS) (Sbisa et al., 1997; Roberti et al., 
1998). 
1.2.2 Mitochondrial Haplogroups 
The mitochondrial genome accumulates mutations at a significantly faster rate 
compared to the nuclear genome (Howell et al., 1996; Jazin et al., 1998). Several 
factors contribute to this higher mutational rate: the absence of protective histones, the 
lack of effective repair mechanisms, and the close proximity of mtDNA molecules to 
the respiratory chain complexes where they are exposed to high levels of reactive 
oxygen species (ROS) (Raha and Robinson, 2000). The mutational rate varies between 
different mtDNA regions, and it is much faster within the two hypervariable regions 
(HVR I and II) of the D-loop where a mutation is estimated to occur every 30 maternal 
generations (Parsons et al., 1997; Siguroardottir et al., 2000). MtDNA is therefore 
highly polymorphic, and during human evolution, a number of relatively benign 
mitochondrial sequence variants have become fixed in different populations. As 
mtDNA is maternally inherited, these polymorphisms have accumulated sequentially 
along radiating female lineages, following the pattern of human migration from Africa 
into the various continents some 150,000 years ago (Cann, 2001). The human 
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phylogenetic tree contains 18 major mtDNA haplogroups, and these comprise a total of 
497 haplogroup-defining polymorphic variants (Torroni and Wallace, 1994; Herrnstadt 
and Howell, 2004). Individuals of European ancestry belong to one of nine 
haplogroups: H, I, J, K, T, U, V, W and X, with haplogroup H accounting for nearly 
half of all cases (Torroni and Wallace, 1994; Herrnstadt et al., 2002). 
 
 
Figure 3. The human mitochondrial genome. Protein coding (yellow), rRNA 
(red), and tRNA (purple) genes are depicted on the heavy (H-, outer) and light 
(L-, inner) strands. The 22 tRNAs are indicated by their cognate amino acid 
letter code and the 2 rRNAs by their sedimentation coefficients (12S and 16S). 
The origins of mtDNA replication and the direction of synthesis are denoted by 
OH for the H-strand, and OL for the L-strand. Reproduced from Kirkman et al 
(2008). 
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1.2.3 Mitochondrial DNA Mutations 
The first pathogenic mutations linked to human disease were identified in 1988. In two 
landmark papers, Holt and colleagues found mtDNA deletions in nine patients with 
mitochondrial myopathy (Holt et al., 1988), and Wallace and colleagues confirmed the 
m.11778G>A point mutation as the causative genetic defect in families with Leber 
hereditary optic neuropathy (LHON) (Wallace et al., 1988). Over the next two decades, 
a large number of pathogenic mtDNA variants have been identified, both point 
mutations and large-scale rearrangements: deletions, insertions, duplications and 
inversions (DiMauro and Schon, 2003; Taylor and Turnbull, 2005). The distribution of 
these pathogenic mutations is not uniform, and several, so-called “mutational hotspots” 
have been identified, which have been associated with specific clinical phenotypes. For 
example, MTND1 and MTND6 harbour the primary m.3460G>A and m.14484T>C 
LHON mutations respectively, but several, other LHON-causing mutations have also 
been identified in these two gene regions (Yu-Wai-Man et al., 2009; Fraser et al., 
2010). The genetic heterogeneity and phenotypic variability of primary mtDNA 
disorders represent significant diagnostic challenges, and these are detailed further in 
later sections of this review. 
1.2.4 Mitochondrial Heteroplasmy 
There are ~ 10,000 mtDNA molecules per cell, with each mitochondrion containing 
multiple copies. Two possible situations can therefore arise, known as homoplasmy 
and heteroplasmy (Lightowlers et al., 1997; Chinnery, 2002). In the heteroplasmic 
state, two or more mtDNA variants are present at a specific nucleotide position, and 
the same phenomenon can also occur for mtDNA re-arrangements. Using different 
molecular assays, heteroplasmy can be quantified in a tissue both at the homogenate 
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and at the single-cell level, and it is not unusual for significant variations to be 
observed between different tissues from the same individual (Chinnery et al., 1999c; 
Krishnan et al., 2007; Greaves et al., 2010). These regional differences are thought to 
partly contribute to the variable clinical features observed in patients with 
mitochondrial disorders (Chinnery et al., 1999c; McFarland et al., 2002). 
1.2.5 Threshold Effect 
Most pathogenic mtDNA mutations are heteroplasmic, a feature which supports the 
concept of a mutational threshold for pathogenicity (Chinnery et al., 2000a; Taylor and 
Turnbull, 2005).  The relationship between mutational load and respiratory chain 
activity has been extensively investigated in different tissues, and the deleterious 
consequences of most mtDNA mutations on OXPHOS usually become apparent when 
the proportion of the mutant species exceeds 60% to 80% (Shoubridge et al., 1990; 
Bua et al., 2006; Durham et al., 2007). There are mutation- and tissue-specific 
variations in this biochemical threshold (Corral-debrinski et al., 1992; Wang et al., 
2001; Nekhaeva et al., 2002), and although these could account for the pattern of organ 
involvement and clinical severity associated with a particular genetic defect, the 
molecular mechanisms are much more complex. A notable example is LHON, which is 
the  most common of the primary mtDNA diseases (Man et al., 2003; Schaefer et al., 
2004; Schaefer et al., 2008). The majority of patients (90-95%) harbour one of three 
mtDNA point mutations: m.3460G>A (MTND1), m.11778G>A (MTND4), and 
m.14484T>C (MTND6), but only ~ 50% of male carriers, and ~ 10% of female carriers 
will experience visual loss during their lifetime (Yu-Wai-Man et al., 2009; Fraser et al., 
2010). Although the risk of blindness is minimal if the mutational load is less than 60% 
(Chinnery et al., 2001), the majority of unaffected carriers (85-90%) are homoplasmic 
 
13 
for the primary LHON mutation (Smith et al., 1993; Harding et al., 1995; Man et al., 
2003), clearly implicating other precipitating factors for optic nerve degeneration. 
1.3 Mitochondrial Inheritance 
1.3.1 Maternal Transmission 
MtDNA is maternally inherited as sperm mitochondria are destroyed by an efficient 
ubiquitin-dependant mechanism following successful oocyte fertilization (Giles et al., 
1980; Sutovsky et al., 1996). Although this fact remains central to genetic counselling 
of families with primary mtDNA disorders, there is one confirmed report of paternal 
inheritance in the literature (Schwartz and Vissing, 2002). In this unique case,  a 28-
year-old man with mitochondrial myopathy was found to harbour a novel 2-base pair 
(bp) mtDNA deletion in MTND2, and remarkably, the mutation was shown to be of 
paternal origin. It was heteroplasmic, present at levels of 90% in the patient‟s muscle 
mtDNA, but was absent in other tissues including blood, hair roots, and cultured 
fibroblasts. Subsequent studies of larger patient cohorts did not reveal evidence of 
paternal mtDNA transmission, confirming that this is a rare molecular occurrence 
(Taylor et al., 2003c; Schwartz and Vissing, 2004). 
1.3.2 Mitochondrial Bottleneck 
Mothers harbouring heteroplasmic mtDNA variants can transmit a wide range of 
heteroplasmy levels to their offpsring, and these rapid shifts in mitochondrial allele 
frequencies have been explained by a “mitochondrial bottleneck” in the germline 
(Jenuth et al., 1996; Jenuth et al., 1997). This bottleneck is thought to be a protective 
mechanism which allows the rapid removal of deleterious mtDNA mutations from the 
genetic pool (Khrapko, 2008; Cree et al., 2009). A pathogenic mtDNA variant would 
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either be lost during transmission to the next generation, or it would quickly reach 
suprathreshold levels within an oocyte, resulting in developmental arrest and its likely 
elimination. Even if a mature oocyte carrying a high proportion of the mutant species is 
successfully fertilised and a live birth results, there is a high probability that the 
affected individual‟s fertility will be subnormal, which again serves to limit the 
transmission of mtDNA mutations. 
A fertilised oocyte contains ~ 250,000 copies of the mitochondrial genome, and from a 
population genetic perspective, the rate of genetic drift for such a large pool of mtDNA 
molecules would be very slow (Khrapko, 2008; Cree et al., 2009). Based on recent 
experimental evidence, different models have been put forward to explain how the 
rapid segregation of new genotypes ascribed to the mitochondrial bottleneck could 
arise. Although there is still some controversy regarding the actual mechanisms and 
developmental timing, some broad observations can still be made (Khrapko, 2008; 
Samuels et al., 2010). Following fertilisation, rapid cell division occurs in the absence 
of mtDNA replication, and the mtDNA pool is simply distributed to the daughter cells 
in these initial phases of mammalian embryogenesis. At around day 7.25 post 
conception (E7.25) in mice, and E20 in humans, the first committed germ-line 
precursor cells in mammals become identifiable, know as primordial germ cells 
(PGCs). In three independent studies in mice, mtDNA copy number was determined at 
different stages of germ cell formation and different results were obtained (Cao et al., 
2007; Cree et al., 2008; Wai et al., 2008). In one study by Cao and colleagues, the 
mtDNA content of PGCs at E7.5 was estimated at ~ 2,000 copies (Cao et al., 2007). 
Although this represents a significant decrease in the mtDNA population, it was still 
ten times higher than the predicted value of ~ 200 required to generate the rapid shifts 
in allele frequencies previously observed in heteroplasmic mice transmitting neutral 
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mtDNA polymorphisms. The authors of that study concluded that the actual 
segregating units were not individual mtDNA molecules, but were in fact aggregates of 
several mtDNA molecules packaged together in structures known as nucleoids (Cao et 
al., 2007). In a second study by Cree and colleagues, which used different experimental 
techniques for the detection and isolation of PGCs, the median mtDNA content of 
individual PGCs at E7.5 was 203 (Cree et al., 2008). The rapid genetic drift in the 
germ line could therefore be explained by this dramatic reduction in copy number, 
without the need for nucleoids. In a third study, a completely different conclusion was 
reached by Wai and colleagues, and the genetic bottleneck was proposed to occur 
during postnatal folliculogenesis, and not during prenatal embryonic oogenesis (Wai et 
al., 2008). A better understanding of the mitochondrial genetic bottleneck is essential 
to current attempts at preventing the transmission of pathogenic mtDNA mutations, 
and additional studies are currently underway to clarify these fundamental research 
questions (Khrapko, 2008).  
Irrespective of the actual nature of the mitochondrial genetic bottleneck, the fate of a 
specific mtDNA variant also depends on whether mtDNA segregation is a truly 
stochastic event, or whether there is active selective pressures either for or against the 
variant. A number of studies in both mice (Jenuth et al., 1996; Jenuth et al., 1997), and 
humans (Chinnery et al., 2000b; Brown et al., 2001), support random genetic drift for 
both neutral and pathogenic mtDNA variants in the female germline. However, two 
recent reports have led to a re-evaluation of the role of selection in the transmission of 
mtDNA variants. The mutator mouse is homozygous for a knock-in allele expressing a 
proofreading-deficient mtDNA polymerase gamma (PolgA), as a result of which it 
accumulates high levels of somatic mtDNA point mutations. In this mouse model, 
transmission of heteroplasmic mtDNA point mutations were subject to strong purifying 
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selection, with the rapid loss of non-synonymous mutations involving protein coding 
genes, compared to those located within tRNA and rRNA genes (Stewart et al., 2008). 
Similarly, in a trans-mitochondrial mouse model, a homoplasmic MTND6 point 
mutation, with a marked effect on complex I activity, was rapidly eliminated from the 
maternal germline, whereas a milder MTCOI mutation was successfully transmitted 
over successive generations (Fan et al., 2008). As for most biological phenomena, the 
situation is likely to be more complex, and it is possible that random genetic drift and 
selection operate in different settings, influenced by mutation-, tissue-, and species-
specific factors (Cree et al., 2009; Fukui and Moraes, 2009). 
1.4 Mitochondrial DNA Maintenance 
1.4.1 Mitochondrial Nucleoids 
MtDNA molecules do not exist in isolation but they are packaged within intricate 
replicative structures known as nucleoids (Gilkerson, 2009). The components of these 
nucleoid structures are being actively investigated, and the mitochondrial protein 
TFAM has been identified as a major nucleoid-organizing protein (Wang and 
Bogenhagen, 2006; Bogenhagen et al., 2008; Kasashima et al., 2008). Several proteins 
with critical roles in mtDNA replication are also associated with mammalian 
nucleoids, and these include: (i) the mitochondrial polymerase- (POLG), (ii) the 
twinkle 5′ → 3′ helicase, which unwinds double-stranded mtDNA at the replication 
fork, (iii) the mitochondrial single-stranded binding (mtSSB) protein, and (iv) the 
accessory topoisomerase and ligase proteins (Tyynismaa et al., 2004; Hudson and 
Chinnery, 2006). Other potential nucleoid-associated proteins include ATAD3, which 
is thought to bind to the mitochondrial D-Loop, regulating both mtDNA transcription 
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and replication (He et al., 2007), and the pro-apoptotic p53 protein, which mediates 
important signalling pathways activated by DNA damage and cellular hypoxia 
(Yoshida et al., 2003). Although this core list is constantly being updated, there is a 
degree of controversy, centred on the purification methods and the cell lines used, 
about which of these proteins truly represent bona fide nucleoid-associated proteins. 
Additional studies are needed to clarify the processes which control the assembly and 
structural organization of mitochondrial nucleoids. 
1.4.2 Mitochondrial DNA Replication 
MtDNA replication is independent of the phase of the cell cycle, occurring in both 
mitotic and post-mitotic tissues, albeit at different rates (Wang et al., 1997). Two main 
models have been proposed for replication of the mitochondrial genome: an 
asynchronous, strand-displacement mode of replication (Clayton, 1982), and a 
synchronous, strand-coupled mode of replication (Holt et al., 2000). This area of 
mitochondrial research remains highly controversial, and there is currently no 
agreement on which model actual operates in vivo. 
According to the Clayton model, replication is initiated within the D-Loop at the 
heavy-strand origin of replication (OH), and it results in the formation of a “leading” H-
strand (Lee and Clayton, 1998; Brown et al., 2005). The extension of this single DNA 
strand proceeds in a clockwise direction until the light-strand origin of replication 
origin (OL) becomes exposed (Figure 4a-c). Replication of the “lagging” L-strand then 
starts in the opposite direction, with replication of the “leading” H strand being nearly 
two-thirds complete. Due to the asynchronous nature of this mechanism, one of the two 
daughter mtDNA molecules will be completed first, with the entire replication cycle 
estimated at about two hours. 
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A modification of the Clayton model has recently been proposed termed RITOLS for 
ribonucleotide incorporation throughout the lagging strand (Yasukawa et al., 2006). 
This RITOLS model is similar to the original strand-displacement mode of replication, 
with a significant delay between leading and lagging strand synthesis. However, the 
defining feature of RITOLS is the incorporation of RNA, instead of DNA, throughout 
the lagging strand (Figure 4). During the maturation phase, these RNA segments are 
then converted to DNA, the conversion process starting in the vicinity of the OL (Yang 
et al., 2002; Yasukawa et al., 2006). 
The strand-coupled model of mtDNA replication is a more novel proposition put 
forward by Holt and colleagues (Holt et al., 2000; Holt et al., 2004). Using two-
dimensional agarose gel electrophoresis (2D-AGE), this group of investigators studied 
the nature of partially single-stranded replication intermediates (RIs) detected in 
mammalian mitochondria. The predominant RIs they identified were consistent with a 
model of replication where synthesis of both the H- and L-strands occurred 
simultaneously, starting within a single zone of replication initiation (oriZ), and 
proceeding in parallel around the mitochondrial genome (Figure 4d). However, it is 
important to note that the original study by Holt and colleagues (Holt et al., 2000), 
outlining the synchronous OriZ mode of replication, does not preclude the joint 
occurrence, at the cellular level, of the more conventional strand-coupled model of 
mtDNA synthesis. 
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Figure 4. Proposed models of mtDNA replication: (a-c) Asynchronous model. 
Replication begins in the D loop at OH and displaces the light strand from the 
heavy strand. The light strand is single stranded until synthesis of the nascent 
heavy strand exposes OL. At this point, replication of the light strand begins in 
the opposite direction until both strands have been fully replicated; (d) 
Synchronous or strand-coupled model. Replication is initiated within a single 
zone of replication (oriZ) and proceeds bi-directionally via conventional coupled 
leading- and lagging-strand synthesis; (e-g) RITOLS model. Replication starts 
in the non-coding region close to or at OH. The RITOLS model is similar to the 
asynchronous model of mtDNA replication, but RNA intermediates are 
produced (dashed lines) on the light strand before being converted to DNA. 
Reproduced from Krishnan et al (2008). 
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1.4.3 Mitochondrial Nucleotide Pools 
The faithful replication of the mitochondrial genome is critically dependent upon a 
balanced supply of deoxyribonucleotides (dNTPs), the „„building blocks‟‟ of mtDNA. 
Mitochondria are unable to synthesize dNTPs de novo and there is a constant need for 
the right balance of dNTPs to sustain mtDNA replication, which occurs throughout the 
cell cycle (Alberio et al., 2007). It is therefore not surprising that over the past decade, 
several nuclear genes have been identified (TYMP, DGUOK, TK2, SUCLA2, SUCLG1, 
and RRM2B),  which  cause mitochondrial depletion syndromes (MDS) due to their 
deleterious consequences on the synthesis and maintenance of these intramitochondrial 
nucleotide pools (Figure 5) (Ashley et al., 2007; Spinazzola and Zeviani, 2009). 
There are distinct nucleotide pools for the nuclear and mitochondrial genomes. The 
mitochondrial dNTPs are formed by the salvage of deoxyribonucleosides, a process 
mediated by four different deoxynucleoside kinases (Rampazzo et al., 2004). 
Thymidine kinase 1 (TK1) and deoxycytidine kinase (dCK) are located in the cytosol, 
and their products are imported into the mitochondrial matrix in order to become 
available for mtDNA synthesis. Thymidine kinase 2 (TK2) and deoxyguanosine kinase 
(dGK) are present within the mitochondrial matrix, and they catalyze the salvage 
pathways for pyrimidine and purine nucleosides, respectively. These mitochondrion-
specific salvage pathways are very important as they represent the major source of 
dNTP precursors in stable tissues such as liver, brain, and muscle. Consistent with 
these critical functions, two Tk2-defective mouse models have recently been reported, 
characterised by mtDNA depletion in a range of tissues, and death within two to four 
weeks secondary to multi-organ failure (Akman et al., 2008; Zhou et al., 2008). 
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Figure 5. The major metabolic and enzyme pathways responsible for 
maintaining the intramitochondrial nucleotide pools. ANT1: adenine nucleotide 
translocator 1; dNMP, dNDP, and dNTP: mono-, di- and tri-phosphate 
deoxynucleotides; mtSSB: mitochondrial single-stranded binding protein; 
NDPK: nucleoside diphosphate kinase; RR: ribonucleotide reductase; SCS: 
succinate CoA synthase isoforms encoded by SUCLA2 and SUCLG1; TP: 
thymidine phosphorylase; T, dU, dC, dG, and dA: deoxynucleosides. 
Reproduced from Spinazzola et al (2009). 
 
RRM2B codes for the small p53-inducible subunit of ribonucleotide reductase (RR), a 
heterotetrameric cytosolic enzyme involved in the terminal steps of de novo dNTP 
synthesis. The ribonucleotide reductase enzyme converts ribonucleoside diphosphates 
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into the corresponding deoxyribonucleoside diphosphates during the S phase of the cell 
cycle (Tanaka et al., 2000). SCS-A and SCS-G, which are encoded by SUCLA2 and 
SUCLG1, are also involved in the last step of the mitochondrial dNTP salvage pathway 
(Alberio et al., 2007; Spinazzola and Zeviani, 2009). Both proteins are associated with 
nucleoside diphosphate kinase (NDPK), a  ubiquitous protein kinase which catalyzes 
the exchange of terminal phosphates between tri- and di-phosphoribonucleosides, 
maintaining the homeostasis of ribonucleotides and deoxyribonucleotides within 
mitochondria (Parks et al., 1973). 
1.4.4 Regulation of MtDNA Copy Number 
The mitochondrial genome is a high-copy number genome, and changes in mtDNA 
copy number are closely linked with disease state, with mitochondrial depletion 
representing one end of the spectrum, and mitochondrial proliferation often observed 
as a compensatory cellular mechanism (Spinazzola and Zeviani, 2009). Relatively little 
is currently known about the mechanisms which “sense” mtDNA copy number, and the 
nuclear-mitochondrial interactions involved still need to be clarified (Moraes, 2001). 
Although an over-simplification, the main players which control mtDNA copy number 
have been divided into three main groups: (i) structural nucleoid proteins, for example 
TFAM (Sections 1.4.1), (ii) proteins directly involved in the mtDNA replication 
machinery (Sections 1.4.2), and (iii) proteins which regulate nucleotide metabolism 
(Sections 1.4.3). The central role played by the TFAM protein was confirmed in a 
series of experiments involving heterozygous and homozygous Tfam knockout mice 
(Larsson et al., 1998). Cardiac tissue from heterozygous Tfam mice had a reduced 
mtDNA content, which was associated with a respiratory chain defect, whereas the 
homozygous mutant embryos were embryonically lethal, dying at E10.5 due to severe 
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mtDNA depletion. Although speculative, some investigators have also argued for the 
existence of rate limiting steps in mtDNA replication, on the premise that certain key 
mediators are only present in fixed amounts, and therefore can only support a certain 
number of mtDNA replication cycles (Moraes, 2001). 
1.5 Mitochondrial Transcription 
Mitochondrial transcription is initiated at three major sites, located within 150 bp of 
each other in the D-Loop; one on the L-strand (ITL) at nucleotide position 407, and two 
on the H-strand (ITH1 and ITH2) at nucleotide positions 561 and 638, respectively 
(Montoya et al., 1981; Montoya et al., 1982; Martin et al., 2005). All three initiation 
sites contain a short consensus sequence, 15 bp long, which is essential for 
transcription (Chang and Clayton, 1984; Chang and Clayton, 1985). The two H-strand 
initiation sites allow for independent rRNA and mRNA synthesis. ITH1 is more 
frequently used, producing two tRNAs (tRNA
Phe
 and tRNA
Val
), and the two 
mitochondrial rRNAs, whereas initiation of transcription at ITH2 results in a large 
polycistronic mRNA molecule corresponding to almost all of the H-strand (Montoya et 
al., 1983). This primary mitochondrial transcript is interspersed by tRNAs, which act 
as punctuation marks, delineating the rRNA and protein-coding mRNA sequences, and 
allowing for accurate endodonucleolytic cleavage (Ojala et al., 1980a; Ojala et al., 
1981; Rossmanith et al., 1995). 
Mitochondrial transcription involves a highly intricate machinery and several key 
proteins have been identified. One of these is the mitochondrial RNA polymerase 
(POLRMT), which is recruited to the promoter sites by TFAM (Tiranti et al., 1997; 
Diaz and Moraes, 2008). TFAM itself is bound to regulatory elements upstream of the 
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three initiation sites (ITH1, ITH2, and ITL) to form a protein-DNA complex (Fisher et 
al., 1987). Two other important mitochondrial transcription factors, TFB1M and 
TFB2M, must also be present for transcription to occur effectively (Falkenberg et al., 
2002; Shoubridge, 2002; Ekstrand et al., 2004). TFB1M and TFB2M are thought to 
directly interact with POLRMT, forming a hetero-dimeric structure, which is then 
delivered to the promoter regions occupied by TFAM (Asin-Cayuela and Gustafsson, 
2007). Termination of mtDNA transcription is dependent on the mitochondrial 
transcription terminator factor (MTERF), which occurs in both active and inactive 
forms within mitochondria (Asin-Cayuela et al., 2004). More recently, a new 
transcription terminator factor has been identified (MTERF3), which blocks the 
initiation of mtDNA transcription in vivo (Park et al., 2007). 
1.6 Mitochondrial Translation 
Mitochondrial translation is poorly understood, and the lack of a reliable in vitro 
system has severely limited progress in this area of research. The vast majority of 
subunits  (~ 90) that make up the mitochondrial ribosomes are encoded by the nuclear 
genome, with only two subunits, 12S and 16S, being of mitochondrial origin (O'Brien, 
2003). Translation of mitochondrial  transcripts is initiated by IF2mt, which promotes 
binding of tRNA
Met
 to the small ribosomal subunit, and IF3mt, which facilitates the 
formation of the ribosomal initiation complex (Figure 6) (Christian et al., 2009). The 
extension of the nascent polypeptide chain has so far been shown to involve three 
mitochondrial elongation factors: EF-G1mt, EF-Tumt, and EF-Tsmt, all of which have 
strong homology to their bacterial counterparts (Rorbach et al., 2007). Mitochondrial 
mRNAs contain four stop codons: UAA, UAG, AGA and AGG, but it is not clear how 
termination of mitochondrial translation is activated. One hypothesis is that when the 
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ribosomal machinery encounters a stop codon, release factors induce hydrolysis of the 
newly formed polypeptide (Rorbach et al., 2007; Christian et al., 2009). So far, only 
one of these putative release factors, RF1amt, has been conclusively shown to terminate 
mRNA translation, both in vitro and  in vivo (Soleimanpour-Lichaei et al., 2007). 
 
 
Figure 6. Current model of mitochondrial protein synthesis. (I) Initiation is 
carried out by IF2mt and IF3mt; (II) Elongation of the polypeptide chain is 
regulated by EF-Tumt, EF-Tsmt, and EF-G1mt; (III) Termination of mitochondrial 
translation is facilitated by RF1amt; and (IV) Ribosome recycling requires RRFmt 
and EF-G2mt. A possible role for IF3mt is also indicated as an alternative 
mechanism. Reproduced from Christian et al. (2009). 
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1.7 Somatic MtDNA Abnormalities 
1.7.1 Ageing 
It is now well established that both mtDNA point mutations and deletions accumulate 
with age in a range of tissues including brain, liver, colon, skeletal and cardiac muscle 
(Khrapko et al., 1999; Fayet et al., 2002; Bender et al., 2006; Krishnan et al., 2008; 
Greaves and Turnbull, 2009). Although the underlying mechanisms remain unclear, 
deletions tend to accumulate in post-mitotic tissues, whereas point mutations show a 
predilection for rapidly-dividing mitotic tissues. These mtDNA defects are somatic in 
origin and they can accumulate to high levels within individual cells by a process of 
clonal expansion. When the proportion of the mutant species exceeds a critical 
threshold of 60-80% (Shoubridge et al., 1990; Bua et al., 2006; Durham et al., 2007), a 
biochemical defect becomes apparent, and this can be observed histochemically as 
cytochrome c oxidase (COX) deficiency. Most COX-deficient cells harbour high levels 
of a single point mutation or deletion, but clonal expansion of more than one mutant 
species can occur, possibly related to a higher de novo mutational rate (Reeve et al., 
2008). The increase in COX-deficiency seen with normal ageing varies markedly 
between tissues, and these regional variations probably reflect the different rates and 
thresholds at which mtDNA defects reach phenotypic expression between cell types 
(Krishnan et al., 2008; Greaves and Turnbull, 2009). 
A mitochondrial theory of human ageing has been proposed based on the hypothesis 
that the progressive accumulation of COX-deficient cells has a  deleterious effect on 
overall tissue function, by accelerating the rate of cellular senescence. In support of 
this argument, high levels of mtDNA deletions have recently been identified in 
substantia nigra neurons isolated from both normal aged controls and patients with 
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Parkinson‟s disease, suggesting a contributory role in the process of neuronal loss 
(Bender et al., 2006; Kraytsberg et al., 2006). However, the role of these somatic 
mtDNA abnormalities in the development of Parkinson‟s disease and other 
neurodegenerative disorders require more rigorous functional studies to demonstrate a 
true causal effect on tissue dysfunction (Khrapko and Vijg, 2009; Kukat and 
Trifunovic, 2009). 
1.7.2 Polg Mouse Models 
To clarify the contribution of somatic mtDNA abnormalities to the ageing process, 
independent research groups have created transgenic mouse models carrying different 
proofreading-deficient versions of mtDNA polymerase gamma (PolgA) (Martin and 
Loeb, 2004; Trifunovic et al., 2004; Kujoth et al., 2005). Homozygous mutant mice 
(PolgA
mut
/PolgA
mut
) had a reduced lifespan and developed a premature ageing 
phenotype characterised by weight loss, reduced subcutaneous fat, alopecia, kyphosis 
osteoporosis, anaemia, cardiomyopathy, and infertility. The development of these 
striking features was linked to the accumulation of significantly higher levels of 
somatic mtDNA point mutations (~ 3-5 times) in these mice compared to their wild-
type littermate controls (Trifunovic et al., 2004; Kujoth et al., 2005). Interestingly, 
there was a close correlation between this increased mutational load and the induction 
of pro-apoptotic markers, especially in tissues characterised by rapid cellular turnover 
(Kujoth et al., 2005). However, in a different mutator mouse model, Vermulst and 
colleagues did not replicate this causal link between the level of somatic mtDNA point 
mutations and a reduction in lifespan (Vermulst et al., 2007). In a subsequent study, 
these investigators showed that the main driving force behind the accelerated ageing 
process in their homozygous mutant (PolgA
mut
/PolgA
mut
) mice was the accumulation of 
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high levels of mtDNA deletions (Vermulst et al., 2008). Although there is no doubt 
that somatic mtDNA abnormalities accumulate at a faster rate in all of these mutator 
mouse models, we need to be cautious when extrapolating these findings to humans. 
Future studies will hopefully provide further insight into the role of somatic mtDNA 
point mutations, deletions, or both in the complex, multifactorial process which defines 
human ageing (Khrapko and Vijg, 2007; Khrapko and Vijg, 2009). 
1.7.3 Cancer 
The pathological hallmark of cancer is uncontrolled cellular growth which leads to 
local tissue dysfunction and distant metastatic foci when malignant transformation has 
occurred (Bianchi, 2010). Polyak and colleagues investigated ten human colorectal cell 
lines, and interestingly, somatic mtDNA point mutations were identified in seven of 
these cases (Polyak et al., 1998). The majority of these mutations were homoplasmic, 
and they were not present in healthy tissues, implicating a possible direct role in the 
carcinogenetic process. These mutations were postulated to confer a physiological 
growth advantage to the tumour cells, and with cellular replication occurring rapidly 
over thousands of generations, all wild-type mtDNA would eventually be replaced 
completely by the mutant species i.e. a state of homoplasmy. However, this theory of a 
replicative advantage was challenged by other research groups. Using in silico 
modelling experiments, these investigators argued instead that the high frequency of 
homoplasmic mtDNA mutations in human tumours could simply arise by random 
genetic drift, without the need for selective mechanisms (Coller et al., 2001; Chinnery 
et al., 2002). With the use of deep sequencing technology, which can reliably detect 
levels of heteroplasmy as low as 1%, it has now become apparent that the majority (~ 
90%) of somatic mtDNA point mutations present in human tumours are actually 
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heteroplasmic (He et al., 2010). The significance of these heteroplasmic mtDNA 
variants to tumour development, malignant transformation, and phenotypic severity 
remains to be determined (Bianchi, 2010). 
1.7.4 Nuclear Mitochondrial Disorders 
Nuclear mitochondrial disorders are an important group of human diseases, and they 
often pose significant diagnostic challenges related to their genetic and phenotypic 
heterogeneity (Section 1.10.2). However, a common molecular feature shared by all 
these disorders is impaired mtDNA maintenance, which can lead to a reduction in 
mtDNA copy number, the accumulation of high levels of somatic mtDNA mutations, 
or both (Alberio et al., 2007; Chinnery and Zeviani, 2008; Spinazzola and Zeviani, 
2009). The identification of these quantitative and qualitative mtDNA abnormalities in 
diagnostic specimens is therefore an important finding, suggesting an underlying 
nuclear defect, and helping to direct appropriate molecular genetic testing. MtDNA 
depletion is the pathological hallmark of several early-onset mitochondrial syndromes, 
and the clinical prognosis is often poor, due to the marked bioenergetic crisis caused by 
such a gross reduction in mtDNA copy number (Spinazzola et al., 2009). Interestingly, 
the observed mtDNA depletion can be highly tissue-specific, which partly explains the 
variability in disease presentation and severity. 
A mosaic pattern of COX-deficient fibres is frequently observed in muscle biopsies of 
patients with nuclear-mitochondrial disorders (Section 1.10.5). For nuclear genetic 
defects involving POLG1, POLG2, PEO1, SLC25A4, TYMP, and more recently OPA1, 
the COX-defect is secondary to the accumulation of multiple mtDNA deletions, which 
have clonally expanded within individual cells to reach suprathreshold levels > 70% 
(Horvath et al., 2006; Amati-Bonneau et al., 2008; Hudson et al., 2008; Spinazzola and 
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Zeviani, 2009). These deleted mtDNA species can be detected in homogenate DNA 
samples with Southern blot and long-range PCR, or more accurately quantified at the 
single-fibre level using real-time PCR assays (He et al., 2002; Taylor et al., 2004a; Bua 
et al., 2006). As most mtDNA deletions involve critical tRNA and protein-encoding 
genes, OXPHOS is adversely affected, and this eventually leads to apoptotic cells loss 
and tissue dysfunction. 
Mutations in POLG1 and TYMP have also been linked with the accumulation of 
somatic mtDNA point mutations. In two studies of patients with chronic progressive 
external ophthalmoplegia (CPEO) and confirmed pathogenic POLG1 mutations, most 
of the identified mtDNA point mutations were present at relatively low heteroplasmic 
levels < 50% (Del Bo et al., 2003; Wanrooij et al., 2004). Importantly, these point 
mutations were found at significantly higher levels only in the mitochondrial D-Loop, 
but not in the protein-coding regions. Although still speculative and controversial, 
these point mutations could compromise the replication machinery located within the 
D-Loop, thereby contributing to the formation of mtDNA deletions. 
Nishigaki and colleagues found multiple somatic mtDNA point mutations in 
fibroblasts obtained from patients with TYMP mutations and mitochondrial 
neurogastrointestinal encephalomyopathy (MNGIE), which were not detected in 
unaffected matrilineal relatives (Nishigaki et al., 2003). These point mutations showed 
a specific pattern, the majority being T to C transitions, and usually preceded by 5′-AA 
sequences. These secondary mtDNA abnormalities were thought to be generated 
because TYMP mutations disrupt the metabolism of thymidine, deoxythymidine (dThd) 
and deoxyuridine (dUrd), causing imbalances of the intramitochondrial dNTP pools. 
Similar to the findings in POLG1, these TYMP-associated mtDNA point mutations 
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were heteroplasmic (2-81%), with most being present at levels < 10%. The majority of 
these variants were also predicted to be neutral polymorphisms, precluding a direct 
pathological effect on mitochondrially-encoded subunits of the respiratory chain 
complexes. The functional significance of the increased frequency of somatic mtDNA 
point mutations seen with both POLG1 and TYMP mutations remains unclear, and 
more sophisticated studies at the single cell level are required to address these 
important issues (Hudson and Chinnery, 2006; Chinnery and Zeviani, 2008). It is also 
fascinating that different mutations within the same gene, e.g. POLG1 and TYMP, can 
result in such a varied spectrum of secondary mtDNA abnormalities. The clarification 
of the secondary factors which dictate whether depletion, deletion, or point mutations 
predominate will provide crucial insights into the underlying disease mechanisms in 
nuclear mitochondrial disorders. 
1.8 Mitochondrial DNA Deletions 
1.8.1 Formation 
Most reported mtDNA deletions occur within the major arc of the mitochondrial 
genome between the two proposed origins of replication, OH and OL (Samuels et al., 
2004; Bua et al., 2006; Krishnan et al., 2008) (http://www.mitomap.org/MITOMAP, 
Accessed 31
st
 of August 2010).  The majority of mtDNA deletions are flanked by short 
homologous direct repeat sequences, one of which is removed by the deletion process. 
Class I deletions (40-60%) have perfect repeats, class II deletions (30-40%) have 
imperfect repeats, and class III deletions (10-20%) have no flanking repeat sequences 
(Samuels et al., 2004; Bua et al., 2006; Krishnan et al., 2008). In  a recent study, 
breakpoint sequencing was performed for mtDNA deletions identified in single 
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substantia nigra neurones from three different groups: normal aged controls, patients 
with sporadic Parkinson‟s disease, and a patient with a heterozygous POLG1 mutation 
leading to parkinsonism in association with CPEO and multiple mtDNA deletions 
(Reeve et al., 2008). Interestingly, the deletions identified in these three distinct group 
of subjects shared remarkable similarities, irrespective of the actual breakpoint 
locations. There were no significant differences in the size distribution of these 
deletions, their breakpoint characteristics, the presence or absence of flanking repeat 
sequences, and the length of the repeat sequences. These observations strongly suggest 
a common mechanism for the formation of mtDNA deletions in both ageing and 
disease states. 
A number of hypotheses have been proposed for the formation of mtDNA deletions, 
with the more established ones based on the occurrence of slippage errors during 
replication (Krishnan et al., 2008). Assuming that the Clayton strand-displacement 
model of mtDNA replication is correct (Clayton, 1982),  a slipped-strand replication 
mechanism could explain the formation of these deleted mtDNA species (Figure 7). 
However, if replication is required for the generation of mtDNA deletions, mitotic 
tissues, which are thought to have faster mitochondrial turnover rates (Wang et al., 
1997), would be expected to have higher deletion loads compared to post-mitotic 
tissues. This has not been found to be the case in rapidly dividing colonic crypt 
epithelial cells, which accumulate somatic mtDNA point mutations, but not deletions 
(Taylor et al., 2003a; Greaves et al., 2006). To account for these discrepancies, some 
investigators have proposed an alternative mechanism of deletion formation, which is 
based on oxidative damage causing double-stranded breaks within mtDNA molecules 
(Krishnan et al., 2008). These double-stranded breaks undergo 3′→5′ exonuclease 
degradation, and create neighbouring genomic regions with single DNA strands. 
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Subsequent attempts at repairing these damages are ineffective, and instead they 
contribute to the loss of the intervening mtDNA fragment (Figure 8). 
 
 
Figure 7. Proposed model of mtDNA deletion formation involving a slipped-
strand model of replication. (a) MtDNA molecule showing two direct repeats 
labelled 5′ and 3′; (b) MtDNA replication begins in the D-Loop at OH, displacing 
the light strand from the heavy strand; (c) The single-stranded 3′ repeat of the 
light strand mis-anneals to the newly exposed single-stranded 5′ repeat of the 
heavy strand. This generates a downstream, single-stranded, light-strand loop, 
which is susceptible to strand breaks; (d) The damaged loop is degraded until 
it reaches the double-stranded regions, and ligation of the free ends of the 
heavy strand occurs; (e-f) Replication resumes with the production of a wild 
type and a deleted mtDNA molecule. Reproduced from Krishnan et al (2008). 
 
34 
 
Figure 8. Generation of mtDNA deletions secondary to double-stranded 
breaks. (a) MtDNA molecule showing two direct repeats labelled 5′ and 3′; (b) 
Occurrence of a double-stranded break; (c-d) The double-stranded break is 
susceptible to 3′→5′ exonuclease activity, leading to the production of single 
strands; (e) The 5′- and 3′-repeat sequences can mis-anneal, leading to 
degradation of the unbound single strands, and ligation of the double strands; 
(f) This results in the production of a deleted mtDNA molecule, which contains 
copies of both the 5′ and 3′ repeats. Reproduced from Krishnan et al (2008). 
 
1.8.2 Clonal Expansion 
Once a mtDNA deletion has been generated, it has to reach suprathreshold levels 
within the cell in order to precipitate a biochemical defect. This process of clonal 
expansion within cells is analogous to genetic drift within populations, and two main 
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mechanisms have been proposed. These invoke either random intracellular processes 
(Chinnery and Samuels, 1999; Elson et al., 2001), or a replicative advantage for the 
deleted mtDNA species (Fukui and Moraes, 2009; Nicholas et al., 2009). 
In the random genetic drift model, the mutant mtDNA allele becomes progressively 
fixed within individual cells, and over a period spanning several decades, the average 
mutational load gradually increases. The cell senses an imbalance caused by the 
accumulation of mutant mtDNA molecules, and mitochondrial proliferation is induced 
as a compensatory mechanism to maintain a critical level of wild-type genomes and 
normal respiratory chain function. This so-called “maintenance of wild-type” 
hypothesis is based on relaxed mtDNA replication, and does not require any selective 
pressures. Although mitochondrial proliferation helps to maintain an optimal level of 
wild-type mtDNA, when the mutational load exceeds a certain threshold level, further 
mitochondrial proliferation leads to replication of the mutant species at the expense of 
wild-type mtDNA, resulting in COX-deficiency (Chinnery and Samuels, 1999; Elson 
et al., 2001). It is important to note that the critical ratio of wild-type to mutated 
mtDNA molecules could be different for specific mutations, and it could also vary 
between tissues from the same individual (Durham et al., 2007; Yu-Wai-Man et al., 
2010a). 
In contrast to the random genetic drift model, some investigators favour positive 
selection as the predominant factor in the clonal expansion of mtDNA deletions (Fukui 
and Moraes, 2009; Nicholas et al., 2009). Deleted mtDNA species are smaller, and 
would therefore be expected to replicate faster than full-length, wild-type mtDNA 
molecules (Diaz and Moraes, 2008). A recent study has provided some important data 
supporting a replicative advantage for deleted mtDNA molecules in post-mitotic cells 
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(Fukui and Moraes, 2009). Fukui and Moraes developed a mouse model expressing an 
inducible restriction endonuclease (PstI), which resulted in double-stranded mtDNA 
breaks in neurones, and the formation of  mtDNA deletions. Of major interest, mtDNA 
molecules with larger deletions were found to accumulate faster than those with 
smaller deletions (Fukui and Moraes, 2009). These results clearly imply a replicative 
advantage for smaller mtDNA species, which could play a powerful role in the 
accumulation of mtDNA deletions seen in both human ageing and mitochondrial 
maintenance disorders. 
The process of clonal expansion is central to our understanding of mitochondrial 
genetic disorders, but the current evidence is still limited, with only few studies 
actually using pathological human samples (Krishnan et al., 2008; Nicholas et al., 
2009). Random genetic drift and positive selection are not mutually exclusive, and 
other important factors could further influence the rate of clonal expansion of deleted 
mtDNA species; for example, the degree of compartmentalization of the mitochondrial 
network, which is critically dependent upon the balance between fusion and fission 
(Section 1.9), and the poorly understood mechanisms linked to autophagy which target 
the removal of specific populations of mitochondria (Twig et al., 2008a). 
1.9 Mitochondrial Dynamics 
1.9.1 Fusion and Fission 
Mitochondria form a highly interconnected tubular network throughout the cell, and it 
is a dynamic process, with mitochondrial segments budding and fusing continuously 
(Chan, 2007; Detmer and Chan, 2007; Yu-Wai-Man et al., 2009). Over the past 
decade, key proteins have been identified which regulate this delicate balance between 
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fusion and fission, and several neurodegenerative disorders are now known to be due 
to disturbance in mitochondrial dynamics. The main pro-fusion proteins are mitofusin-
1 (MFN1), mitofusin-2 (MFN2), and OPA1; and the main pro-fission proteins are 
DRP1 and hFIS1 (Chan, 2007; Knott et al., 2008; Twig et al., 2008b). An important 
structural similarity shared by all these proteins is a highly-conserved dynamin-related 
GTPase domain, which is essential for their normal function (Lenaers et al., 2009). 
1.9.2 MFN1 and MFN2 
MFN1 and MFN2 are the highly-conserved, mammalian orthologs of the yeast Fzo1 
protein, and both proteins are localized to the mitochondrial outer membrane (Figure 
9). The amino-terminal region contains the conserved GTPase domain, and the 
carboxy-terminal region, which faces the cytosol, consists of a coiled-coil structure. By 
forming homo- or hetero-typic complexes, these coiled-coil regions allow the tethering 
of neighbouring mitochondria, which is an important initial step in the fusional process 
(Knott et al., 2008; Suen et al., 2008). Disruption of outer membrane fusion leads to 
disease state, and MFN2 mutations (1p36.2) have been identified in an autosomal 
dominant form of Charcot-Marie-Tooth disease (CMT-2A, OMIM 609260) (Zuchner 
et al., 2004). CMT-2A is characterised by axonal degeneration of the peripheral nerves, 
and affected patients experience progressive distal muscle weakness and sensory loss 
(Chung et al., 2006; Verhoeven et al., 2006). Interestingly, MFN2 mutations have also 
been found in families with a different CMT subtype, hereditary sensory motor 
neuropathy type 6 (HSMN-6, OMIM 601152), where the peripheral neuropathy is 
complicated by the development of bilateral optic atrophy, emphasizing the important 
role played by MFN-2 in retinal ganglion cell (RGC) physiology (Zuchner et al., 
2006). 
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Figure 9. Major proteins regulating mitochondrial fusion. The insert shows the 
localization of proteases involved in OPA1 cleavage. mitoPLD: mitochondrial 
phospholipase D; PARL: presenilin-associated rhomboid-like (PARL) protease. 
Reproduced from Suen et al (2008). 
 
Knockout mice lacking functional Mfn1 and Mfn2 have been developed and these 
models have provided important insights into the roles played by the mitofusin proteins 
(Chan, 2006; Chen and Chan, 2009). Homozygous mutant embryos died in utero due 
to placental insufficiency, clearly indicating that Mfn1 and Mfn2 are essential in the 
early stages of  embryonic development (Chen et al., 2003). Cultured mouse 
embryonic fibroblasts (MEFs) showed a highly fragmented mitochondrial network due 
a severe reduction in mitochondrial fusion. This eventually led to a loss of membrane 
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potential in a subpopulation of fragmented mitochondria. The same group of 
investigators subsequently developed a conditional Mfn2 knockout mouse model, using 
a cre-loxP recombinase strategy, which spared placental tissues, allowing normal 
embryonic development (Chen et al., 2007). The Meox2-Cre/Mfn2
loxP
 mutant mice 
showed marked cerebellar degeneration with an aberrant, fragmented mitochondrial 
morphology, which was associated with the loss of mtDNA nucleoids. 
1.9.3 OPA1 
OPA1 was originally characterised in the budding yeast saccharomyces cerevisiae in a 
screen for nuclear genes involved in mtDNA maintenance, and both the human and 
yeast (Mgm1) homologues show a high degree of evolutionary conservation. The 
OPA1 gene (3q28–q29) consists of 30 exons spanning ~ 100Kb of genomic DNA and 
it codes for a 960 amino acid, dynamin-related GTPase protein located within the inner 
mitochondrial membrane (Figure 9) (Davies and Votruba, 2006). Alternative splicing 
of exons 4, 4b and 5b result in eight different mRNA isoforms, and their functional 
relevance and subcellular localisation are currently being investigated (Olichon et al., 
2007a; Olichon et al., 2007b). OPA1 mutations are the most common causes of 
autosomal dominant optic atrophy (DOA, OMIM 165500), and they account for about 
60% of all clinically-diagnosed cases (Alexander et al., 2000; Delettre et al., 2000). 
Over 200 pathogenic mutations have now been identified and these cluster in two 
specific regions: the GTPase region (Exons 8-15), and the carboxy-terminal region 
which is the proposed site of the GTPase effector domain (GED) (Ferre et al., 2005; 
Ferre et al., 2009). 
The native OPA1 protein has an amino-terminal domain with a mitochondrial targeting 
pre-sequence, which is cleaved by mitochondrial proteases following import into the 
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mitochondrial intermembrane space (Olichon et al., 2002; Lenaers et al., 2009). The 
transmembrane domain allows the protein to be firmly anchored to the inner 
mitochondrial membrane, in the narrow junctional regions enclosing the cristae spaces. 
The transmembrane domain is followed by a series of coiled-coil segments, which 
based on crystallographic studies, allow homo-polymerization of the OPA1 protein 
into a cylindrical tubular structure. Mitochondrial membrane proteases lead to further 
maturational processing (Section 1.9.5), which is relevant to the various cellular 
functions mediated by OPA1, in addition to inner membrane fusion (Davies and 
Votruba, 2006; Yu-Wai-Man et al., 2009). It is important to note that outer and inner 
membrane fusion are highly coordinated events, and in order to achieve this, OPA1 
interacts closely with both MFN1 and MFN2, together with other accessory proteins. 
The latter are currently being defined in yeast models (Yaffe, 2003), and it is likely that 
mutations affecting the human orthologues will be associated with inherited 
neurodegenerative diseases. 
1.9.4 DRP1 and hFIS1 
Mitochondrial fission requires the recruitment of two dynamin-related GTPase 
proteins; DRP1 which is found within the cytosol (Pitts et al., 1999; Ishihara et al., 
2009), and hFIS1, which is located within the mitochondrial outer membrane (Koch et 
al., 2005; Serasinghe and Yoon, 2008). DRP1 and hFIS1 are the mammalian 
orthologues of the yeast proteins Dnm1 and Fis1, respectively. The current working 
model of mitochondrial fission involves hFIS1 recruiting DRP1 to the mitochondrial 
outer membrane, with both proteins then assembling into rings and spirals that encircle 
and constrict the mitochondrial tubule (Sesaki and Jensen, 1999; Suen et al., 2008). 
Following GTPase hydrolysis and energy release, these helical structures twist and the 
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conformational changes result in fission (Figure 10). The actual sequence of events is 
likely to be more complex, and additional studies are needed to explore the 
intermediate steps involved, and whether the cytoskeleton plays a significant role in 
facilitating mitochondrial fission. 
 
 
Figure 10. The mitochondrial fission machinery. Reproduced from Suen et al 
(2008). 
 
The role of mitochondrial fission in maintaining cellular homeostatis was confirmed 
further when a heterozygous, dominant-negative, DLP1 mutation was identified in a 
female infant with a complex neurodegenerative phenotype characterised by 
microcephaly, abnormal brain development, optic atrophy, and disturbed metabolic 
function (Waterham et al., 2007).  The mitochondrial network in the patient‟s cultured 
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fibroblasts was elongated, forming tangled, tubular structures, which were clumped 
around the nucleus. 
1.9.5 Mitochondrial Membrane Proteases 
As a result of alternative splicing of exons 4, 4b and 5b, OPA1 exists as eight isoforms, 
and these are further modified by proteolytic cleavage mediated by the mitochondrial 
membrane proteases (Olichon et al., 2007a; Olichon et al., 2007b). These post-
translational maturational steps are highly relevant to OPA1 function, and under 
physiological conditions, two specific splicing variants predominate, which differ for 
the absence (Variant 1), or presence (Variant 7) of exon 5b. Both OPA1 isoforms are 
first processed by the matrix metalloproteinases (MMP), which remove the 
mitochondrial targeting signal, and then by AAA (ATPases associated with a number 
of diverse cellular activities) proteases, which lead to the formation of long (L) and 
short (S) forms of  OPA1 (Martinelli et al., 2009; Martinelli and Rugarli, 2010). On 
their own, the long and short forms of OPA1 have little functional activity, but when 
co-expressed, they complement each other, triggering mitochondrial network fusion 
(Duvezin-Caubet et al., 2006; Duvezin-Caubet et al., 2007; Song et al., 2007). The m-
AAA proteases AFG3L2 and paraplegin cleave OPA1 at site S1 within exon 5, 
whereas the i-AAA protease YME1 cleaves OPA1 at S2 within exon 5b. Of note, 
paraplegin is encoded by SPG7, and mutations in this gene have been identified in a 
subgroup of patients with autosomal recessive hereditary spastic paraplegia (HSP-7, 
OMIM 607259) (Casari et al., 1998). These patients experience progressive weakness 
and spasticity of their lower limbs, due to degeneration of the corticospinal tract axons 
(Arnoldi et al., 2008). A fourth mitochondrial membrane protease related to the yeast 
orthologue Pcp1, the presenilin associated rhomboid-like (PARL) protease, is also 
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involved in OPA1 cleavage (Cipolat et al. 2006, Gottlieb 2006). The pool of soluble 
OPA1 isoforms generated within the intermembrane space by PARL is thought to  
exert a crucial anti-apoptotic influence (Gottlieb, 2006), especially under conditions of 
increased cellular oxidative stress (Section 1.9.7). 
1.9.6 Reactive Oxygen Species 
The shuttling of high-energy electrons along the mitochondrial respiratory chain 
complexes is a potent generator of ROS: superoxide anions (O2
-
), hydroxyl radicals 
(OH

), and hydrogen peroxide (H2O2) (Lee and Wei, 2007; Trifunovic and Larsson, 
2008). These ROS molecules need to be contained by protective cellular mechanisms 
as they are powerful inducers of the apoptotic cascade. Superoxide dismutases (SODs) 
convert superoxide anions into hydrogen peroxide, which in turn can be transformed 
into water by catalase or  members of the glutathione peroxidase enzyme family. The 
cell also contains nonenzymatic scavengers such as ascorbate, pyruvate, flavenoids, 
and carotenoids which are able to inactivate potentially damaging ROS (Trifunovic and 
Larsson, 2008). 
There is no doubt that ROS can have a harmful influence on cell survival by causing 
oxidative damage to lipids, proteins and DNA within tissues. However, the links 
between increased ROS levels, normal ageing, and mitochondrial diseases remain 
controversial (Loeb et al., 2005; Trifunovic and Larsson, 2008). Yarosh and colleagues 
have recently established a drosophila model harbouring a specific dOpa1 mutation 
(CG8479), and the ocular phenotypes associated with heterozygous and homozygous 
carriers were determined (Yarosh et al., 2008). Homozygous mutant flies developed a 
rough and glossy eye phenotype due to the loss of hexagonal lattice cells, and 
decreased lens and pigment deposition. The dOpa1 mutation caused an increase in 
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ROS levels and mitochondrial fragmentation, which damaged both cone and pigment 
cells. In a series of elegant experiments, these investigators were then able to 
demonstrate that the rough and glossy eye phenotype could be partially reversed by 
dietary supplementation with SOD-1 and vitamin E, and by genetic over-expression of 
human SOD1. Heterozygous adult flies did not exhibit any ocular abnormalities, but 
similar to the homozygous mutants, they also demonstrated elevated ROS levels and a 
greater susceptibility to oxidative stress. The heteterozygous drosophila carriers 
showed irregular and dysmorphic mitochondria in their muscle, and they had a 
significantly shortened lifespan, which was only partially restored by antioxidant 
treatment (Shahrestani et al., 2009; Tang et al., 2009). 
Other investigators have however challenged a direct cause and effect relationship 
between increased ROS and ageing (Kujoth et al., 2005; Trifunovic et al., 2005). The 
opposing arguments are based on the observations made on two PolgA mouse models, 
which developed a premature ageing phenotype due to an error-prone, mutant version 
of mtDNA polymerase gamma (Section 1.7.2). Although both PolgA mouse models 
showed marked respiratory chain dysfunction related to  their high somatic mtDNA 
mutational loads, an increase in ROS levels was not observed in affected tissues, and 
there was no up-regulation in the mRNA expression of antioxidant ROS scavengers. 
1.9.7 Apoptosis 
By controlling the release of several pro-apoptotic effectors such as cytochrome c, 
smac/DIABLO, and AIF (Apoptosis inducing factor),  mitochondria play a central role 
in regulating the apoptotic cascade which precipitates neuronal loss (Figure 11) 
(Hengartner, 2000; Lee and Wei, 2007; Wang and Youle, 2009). Although the 
mitochondrial apoptotic pathway is well established, it is only over the past few years 
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that a close link has emerged between mitochondrial dynamics and these key activation 
events. Cytochrome c molecules are sequestered within the mitochondrial cristae, and 
OPA1 is an integral component of the junctional complexes which prevent their release 
into the cytosolic compartment. OPA1 oligomers maintain the tightness of these cristae 
junctions, thereby counteracting the actions of BID, a pro-apoptotic BCL-2 family 
member (Cipolat et al., 2006). In addition, PARL, which is a major mitochondrial 
membrane protease, has been shown to mediate cristae remodelling via proteolytic 
cleavage of OPA1 (Cipolat et al., 2006). 
Parl
-/-
 knockout mice developed progressive, generalized cachexia, and they died 
prematurely secondary to multi-system atrophy (Cipolat et al., 2006; Gottlieb, 2006). 
Although Parl
-/-
 null cells displayed normal mitochondrial morphology, they were 
sensitized to intrinsic apoptotic death stimuli triggered by etoposide, staurosporine, and 
hydrogen peroxide. Parl deficiency led to the unopposed leakage of cytochrome c from 
the cristae compartments, resulting in massive cellular apoptosis. The anti-apoptotic 
properties of OPA1 was further confirmed by Yamaguchi and colleagues, who showed 
that the pro-apoptotic peptides, Bid and Bim, induced cytochrome c release in mouse 
hepatocytes by triggering the disassembly of murine Opa1 complexes (Lee and Wei, 
2007; Yamaguchi et al., 2008). 
Co-immunoprecipitation studies indicate that OPA1 interacts directly with AIF, 
highlighting an important pathophysiological link between OPA1 mutations and 
apoptotic RGC loss. Interestingly, both OPA1 and AIF are thought to be involved in 
complex I assembly and maintenance, reinforcing the overlapping properties of these 
two proteins (Vahsen et al., 2004; Zanna et al., 2008). The reliance of RGC survival on 
normal levels of AIF was elegantly demonstrated in the Harlequin (Hq) mouse model, 
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which contains a proviral insertion in Aif, resulting in a dramatic reduction (~80%) in 
gene expression (Klein et al., 2002). At three months of age, Hq mutant mice were 
exhibiting progressive RGC loss, and retinal degeneration became more severe by 11 
months of age, eventually involving both the inner and outer plexiform layers. At that 
late stage, full field electroretinography confirmed complete loss of both rods and 
cones responses. Neuronal death in this Hq mouse model has been linked with 
increased oxidative stress, suggesting that AIF serves as a free radical scavenger under 
conditions of heightened cellular stress. 
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Figure 11. Schematic overview of the main mitochondrion-mediated and 
mitochondrion-independent apoptotic pathways. The death-receptor pathway is 
triggered by members of the death receptor superfamily such as CD95. 
Binding of the CD95 receptor ligand induces receptor clustering and formation 
of a death-inducing signalling complex. This complex recruits, via the adaptor 
molecule FADD (Fas-associated death domain protein), multiple procaspase-8 
molecules, resulting in caspase-8 activation. The death-receptor and 
mitochondrial pathways converge at the level of caspase-3 activation. 
Downstream of caspase-3, the apoptotic programme branches into a multitude 
of subprogrammes, the sum of which results in the ordered dismantling and 
removal of the cell. Reproduced from Hengartner et al (2000). 
 
1.10 Mitochondrial Diseases 
1.10.1 Epidemiology 
Several epidemiological studies have confirmed that pathogenic mitochondrial DNA 
(mtDNA) mutations are major causes of human disease, with a minimum prevalence in 
the general population of 1 in 5000 (Schaefer et al., 2004; Schaefer et al., 2008). In a 
recent study of 3000 umbilical cord blood samples from a Cumbrian birth cohort in 
England, about 1 in 200 healthy neonates were found to harbour pathogenic mtDNA 
alleles, and these arose de novo almost every 1000 births (Elliott et al., 2008). In a 
tertiary diagnostic centre, the majority of patients with adult-onset mitochondrial 
disorders had primary mtDNA mutations (~ 75%), but this figure was significantly 
lower (~ 20%) among children with confirmed respiratory chain defects (Schaefer et 
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al., 2004; Schaefer et al., 2008). The remaining cases are likely to harbour nuclear 
genetic defects, and a growing number of these have been mapped and characterised 
over the past decade (McFarland et al., 2007; Zeviani and Carelli, 2007). With the 
exception of  POLG1 (Horvath et al., 2006), and OPA1 (Yu-Wai-Man et al., 2010b), 
mutations in these nuclear genes are individually rare, but as a group, they are 
increasingly being recognised and diagnosed by clinicians. As molecular genetic 
testing becomes more widely available, and new disease genes are identified, it is very 
likely that nuclear mitochondrial disorders will prove to be at least as common as 
primary mitochondrial disorders. 
1.10.2 Classification 
Mitochondrial genetic disorders are classified into two major groups: primary 
mitochondrial disorders and nuclear mitochondrial disorders (Tables 2 and 3). In 
2001, the first nuclear genes, POLG1 and PEO1, were identified among families with 
autosomal dominant CPEO associated with multiple mtDNA deletions (Spelbrink et 
al., 2001; Van Goethem et al., 2001). Since then, the number of genes causing nuclear 
mitochondrial disorders has been expanding continuously, allowing significant 
progress to be made in elucidating the fundamental mechanisms that underpin 
mitochondrial physiology in both normal and disease states. As a result, we have 
gained a better understanding of the complex interactions between subunits of the 
respiratory chain complexes, and the crucial role played by accessory proteins in 
ensuring their proper assembly and stability along the inner mitochondrial membrane. 
These sometimes rare neurodegenerative and metabolic disorders have also provided 
important insights into the molecular components required for mtDNA maintenance, 
and the translational machinery that regulates intra-mitochondrial protein synthesis. 
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Table 2. Primary mitochondrial disorders 
 Inheritance  
Rearrangements (Large-scale partial deletions and duplications)  
 Chronic progressive external ophthalmoplegia (CPEO) S or M 
 Kearns-Sayre syndrome  S or M 
 Diabetes and deafness   S 
 Pearson marrow-pancreas syndrome  S or M 
 Sporadic tubulopathy  S 
  
Point mutations    
Protein-encoding genes   
 LHON (m.11778G>A, m.14484T>C, m.3460G>A)  M 
 NARP/Leigh syndrome (m.8993T>G/C) M 
tRNA genes   
 MELAS (m.3243A>G, m.3271T>C, m.3251A>G)  M 
 MERRF (m.8344A>G, m.8356T>C)   M 
 CPEO (m.3243A>G, m.4274T>C)   M 
 Myopathy (m.14709T>C, m.12320A>G)  M 
 Cardiomyopathy (m.3243A>G, m.4269A>G, m.4300A>G)  M 
 Diabetes and deafness (m.3243A>G, m.12258C>A) M 
 Encephalomyopathy (m.1606G>A, m.10010T>C)  M 
rRNA genes     
 Non-syndromic sensorineural deafness (m.7445A>G) M 
 Aminoglycoside-induced non-syndromic deafness (m.1555A>G) M 
M = Maternal, S = Sporadic. MtDNA nucleotide positions refer to the L-chain, and are 
taken from the Cambridge reference sequence. LHON = Leber hereditary optic 
neuropathy, MELAS = Mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes, MERRF = Myoclonic epilepsy with ragged red fibres, NARP = 
Neurogenic weakness with ataxia and retinitis pigmentosa. 
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Table 3. Nuclear mitochondrial disorders 
Mutations involving structural subunits of the mitochondrial respiratory chain 
Leigh syndrome: with complex I deficiency – mutations in NDUFS1, NDUFS4, 
NDUFS7, NDUFS8, NDUFV1; with complex II deficiency – mutations in SDHA 
Cardiomyopathy and encephalopathy with complex I deficiency – mutations in 
NDFUS2 
Optic atrophy and ataxia with complex II deficiency – mutations in SDHA 
Hypokalaemia and lactic acidosis with complex III deficiency – mutations in 
UQCRB 
 
Mutations involving assembly factors of the mitochondrial respiratory chain 
Leigh syndrome – mutations in SURF I and LRPPRC 
Hepatopathy and ketoacidosis – mutations in SCO1 
Cardiomyopathy and encephalopathy – mutations in SCO2 
Leukodystrophy and renal tubulopathy – mutations in COX10 
Hypertrophic cardiomyopathy – mutations in COX15 
Encephalopathy, liver failure, and renal tubulopathy with complex III deficiency – 
mutations in BCS1L 
Encephalopathy with complex V deficiency – mutations in ATP12 
 
Nuclear genetic disorders of intra-mitochondrial protein synthesis: 
Leigh syndrome, liver failure, and lactic acidosis – mutations in EFG1 
Lactic acidosis, developmental failure, and dysmorphism – mutations in MRPS16 
Myopathy and sideroblastic anaemia – mutations in PUS1 
Leukodystrophy and polymicrogyria – mutations in EFTu 
Encephalomyopathy and hypertrophic cardiomyopathy – mutations in EFTs 
Edema, hypotonia, cardiomyopathy, and tubulopathy – mutations in MRPS22 
Hypotonia, renal tubulopathy, and lactic acidosis – mutations in RRM2B 
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Nuclear genetic disorders of mitochondrial protein import 
Mohr-Tranebjaerg syndrome or deafness-dystonia-optic neuronopathy (DDON) 
syndrome – mutations in TIMM8A (DDP) 
Early-onset dilated cardiomyopathy with ataxia (DCMA) or 3-methylglutaconic 
aciduria, type V – mutations in DNAJC19 
 
Nuclear genetic disorders of mitochondrial DNA maintenance 
Chronic progressive external ophthalmoplegia – mutations in POLG1, POLG2, 
PEO1, SLC25A4, RRM2B, and OPA1 
Mitochondrial neurogastrointestinal encephalomyopathy – mutations in TYMP 
Alpers syndrome – mutations in POLG1 and MPV17 
Infantile myopathy and spinal muscular atrophy – mutations in TK2 
Encephalomyopathy and liver failure – mutations in DGUOK 
Hypotonia, movement disorder and/or Leigh syndrome with methylmalonic 
aciduria – mutations in SUCLA2 and SUCLG1 
Optic atrophy, deafness, chronic progressive external ophthalmoplegia, myopathy, 
ataxia, and peripheral neuropathy – mutations in OPA1 
 
Miscellaneous 
Co-enzyme Q10 deficiency – mutations in PDSS2, APTX, COQ2, and ETFDH 
Barth syndrome – mutations in TAZ 
Cardiomyopathy and lactic acidosis associated with mitochondrial phosphate 
carrier deficiency – mutations in SLC25A3 
Alpers syndrome: epilepsy, cortical blindness, micronodular hepatic cirrhosis, episodic 
psychomotor regression; Barth syndrome: cardiomyopathy, hypotonia, weakness, and 
neutropenia. 
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1.10.3 Clinical Manifestations 
Mitochondrial genetic disorders can affect any organ system and the heterogeneous 
clinical features seen are frequently compounded by marked inter- and intra-familial 
phenotypic variability (Figure 12). An underlying mitochondrial aetiology should 
therefore be considered in all patients with complex, multi-system presentations, 
especially those with neuromuscular, ocular and endocrine involvement. From a 
practical diagnostic standpoint, the possibility of a primary or nuclear mitochondrial 
genetic defect should be considered  in the following three groups of patients 
(Chinnery et al., 1999a; McFarland et al., 2002; Kirkman et al., 2008). The first group 
includes patients with classic presentations which strongly suggest an underlying 
mitochondrial aetiology. For example, bilateral, sequential, and severe visual failure in 
a young adult male, with clear-cut evidence of optic nerve dysfunction is highly 
suggestive of LHON (Yu-Wai-Man et al., 2009). Similarly, a history of slowly 
progressive, bilateral, symmetrical ptosis, with marked restriction of extraocular 
movements in a middle-aged adult, is pretty characteristic for CPEO, and this 
diagnosis should be considered as part of the differential diagnosis. If CPEO develops 
at a younger age, before the age of twenty, in association with pigmentary retinopathy 
and cardiac conduction defects, a diagnosis of Kearns-Sayre syndrome can be made 
easily on clinical grounds (Fraser et al., 2010). 
In the second group, patients do not fall into any specific mitochondrial syndromes, but 
instead, they develop a collection of clinical features which are highly suggestive of an 
underlying respiratory chain defect, such as a combination of proximal myopathy, 
cardiomyopathy, and sensorineural deafness. The third and most challenging group 
includes patients with vague symptoms such as reduced exercise tolerance and 
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myalgia, or presenting with isolated neurological features such as seizures, migraine, 
and peripheral neuropathy, all of which are relatively common in the general 
population. The presentation of mitochondrial genetic disorders in childhood can be 
even more non-specific, with neonatal hypotonia, feeding difficulties, and failure to 
thrive (McFarland et al., 2002; Chinnery and Schon, 2003). Unless there are other 
affected family members with more classical mitochondrial phenotypes, there are often 
significant delays in reaching a molecular diagnosis in this third group of patients. 
 
 
Figure 12. Clinical manifestations of mitochondrial genetic disorders. 
Reproduced from Chinnery and Schon (2003). 
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1.10.4 Diagnostic Investigations 
The investigation of patients with suspected mitochondrial genetic disorders is a 
highly-specialised area, often requiring sophisticated laboratory assays to reach a 
molecular diagnosis (Figure 13). It is therefore crucial to have appropriately trained 
clinician scientists who are able to interpret the results and then guide the referring 
clinicians should further confirmatory studies be required. As a group, mitochondrial 
disorders are extremely heterogeneous, and given the frequent occurrence of ocular 
features in these patients, neuro-ophthalmologists should always consider this 
possibility in their differential diagnosis. A detailed history should be obtained, with 
particular attention paid to the family history, which can often be very revealing, but is 
often not volunteered by patients unless specifically asked for. The aims of ancillary 
testing fall into three broad categories (Figure 14): (i) to objectively delineate the 
severity and pattern of organ involvement, (ii) to exclude possible, treatable 
complications such as cardiac conduction defects and epilepsy, and (iii) to identify the 
nature of the underlying genetic defect with the specific use of histochemical, 
biochemical, and molecular studies (Chinnery et al., 1999a; McFarland et al., 2002; 
Kirkman et al., 2008). 
1.10.5 Mitochondrial Histochemistry 
A muscle biopsy is a powerful diagnostic tool when investigating a patient with a 
suspected mitochondrial aetiology (Taylor et al., 2004b). Open muscle biopsies are not 
routinely performed and the preferred method is a percutaneous approach, using either 
a conchotome or a modified biopsy needle (Dietrichson et al., 1987). The quadriceps 
and tibialis anterior muscles are the most frequently biopsied areas, and if possible, the 
biopsy of an affected muscle group is recommended. 
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Figure 13. Histochemical, biochemical, and molecular genetic investigations of 
patients with suspected mitochondrial disease. Reproduced from McFarland et 
al (2002). 
 
Once retrieved, the muscle specimen is placed in a melting isopentane bath (–150°C) 
to minimize freezing artefacts, before being stored at –80°C. Using a cryostat, serial 
muscle sections, usually 10-20 m thick, are cut onto glass or membrane slides, before 
being stained using various reagents. Stains that are commonly performed in the 
investigation of patients with suspected mitochondrial disorders include: (i) 
haematoxylin and eosin (H&E), (ii) Gomori trichrome, (iii) COX, and (iv) succinate 
dehydrogenase (SDH) (Figure 15). 
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Figure 14. Additional investigations in patients with suspected mitochondrial 
disease. These are tailored according to the patient’s presentation, family 
history, and underlying genetic defect if known. Reproduced from McFarland et 
al (2002). 
 
When indicated, myofibrillar ATPase staining can also be performed to determine the 
distribution of Type I and Type II muscle fibres and identify pathological features such 
as fibre-type grouping, which is seen with denervation of the peripheral nerves 
(Johnson and Barron, 1996; Taylor et al., 2004b). 
H&E provides useful basic information on muscle fibre morphology, whereas the 
Gomori trichrome stain highlights the abnormal accumulation of mitochondria in the 
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subsarcolemmal space, giving the classical appearance of “ragged red fibres” (RRFs) 
(Figure 15). COX and SDH specifically assess mitochondrial enzyme activity, with 
COX-stained fibres appearing brown, and SDH-stained fibres appearing blue. As 
complex II is entirely nuclear-encoded, SDH activity is usually preserved, unless a 
nuclear defect affects one of its four constituent subunits (Birch-Machin et al., 2000; 
Rutter et al., 2010). Pathological RRFs can also be detected with SDH, which has 
largely superseded the Gomori-trichrome stain in many diagnostic laboratories. There 
is a normal variation in COX staining in healthy skeletal muscle, oxidative Type I 
fibres appearing darker brown compared to glycolytic Type II fibres. Loss of COX 
activity is an important marker of mitochondrial dysfunction, and the frequency of 
these COX-negative fibres can be easily quantified with dual COX-SDH staining 
(Figure 15). RRFs are usually COX-negative, but COX-positive RRFs can also occur, 
especially with some mutations such as m.3243A>G. 
The pattern of COX-negative muscle fibres can be a useful preliminary indicator of the 
underlying molecular genetic defect. A mosaic distribution of COX-positive and COX-
negative fibres is usually seen with heteroplasmic mtDNA mutations, and in nuclear 
disorders linked with the accumulation of secondary mtDNA abnormalities (Section 
1.7.4). On the other hand, a generalized decrease in overall COX activity is more 
suggestive of a homoplasmic mitochondrial tRNA mutation (McFarland et al., 2002; 
Taylor et al., 2003b), or a nuclear defect disrupting COX-assembly proteins, e.g. 
SURF1 (Zhu et al., 1998). However, these are only broad generalizations, and patients 
harbouring these genetic defects have also been described whose muscle biopsies were 
completely normal, with no histochemical defect present. 
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Figure 15. Mitochondrial histochemical studies. (A) Ragged-red muscle fibre 
identified using the modified Gomori trichome stain. The red component of the 
staining mixture is selectively sequestered by mitochondria, which have 
accumulated in the subsarcolemmal region, giving the fibre an irregular red 
outline; (B) Serial section of the same muscle fibre shown in (A) after SDH 
staining. This is a more specific assay for detecting the subsarcolemmal 
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accumulation of mitochondria, SDH being a specific marker of complex II 
activity; (C) Normal COX histochemistry with Type I and Type II muscle fibres 
in the cut section; (D) Abnormal COX histochemistry from a patient with CPEO, 
showing a large number of COX-deficient fibres; (E) Serial section of (D) 
following sequential COX-SDH histochemistry. The individual COX-deficient 
fibres are now highlighted blue due to preserved SDH activity; (F) Sequential 
COX-SDH histochemistry revealing a single COX-deficient muscle fibre in a 
section of ageing muscle, emphasizing that caution should be taken in the 
interpretation of muscle biopsies from elderly individuals. All scale bars 30 mm. 
Reproduced from Taylor et al (2004). 
 
1.10.6 Biochemical Studies 
Mitochondrial biochemical studies are fraught with difficulties, the specific protocols 
and normative ranges used varying widely between laboratories worldwide (Taylor et 
al., 2004b; Yu-Wai-Man et al., 2009). The results therefore need to be interpreted 
cautiously in the context of the clinical history and histochemical findings. 
Nevertheless, the measurement of respiratory chain complex activity can be very 
useful, especially in the investigation of children with complex metabolic and 
neurodegenerative disorders. Mitochondrial biochemical studies are usually performed 
on skeletal muscle, and although a fresh sample is preferable, this is not always 
possible when tissue biopsies need to be sent frozen to supra-regional centres. 
Fibroblast cultures are also frequently used, as a skin biopsy is a minimally invasive 
procedure which can be easily performed during a patient‟s outpatient clinic visit. The 
activities of the individual respiratory chain complexes are determined on 
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mitochondrially-enriched suspensions, and they are expressed relative to the activity of 
citrate synthase, a matrix marker enzyme (Janssen et al., 2003; Kirby et al., 2007). 
Depending on the specific genes involved,  mtDNA point mutations and deletions can 
present with either an isolated or multiple complex defects. It is now also possible to 
reliably measure coenzyme Q10 (CoQ10) levels directly in tissues (Musumeci et al., 
2001; Sacconi et al., 2010). 
Given the limitations of in vitro biochemical assays, some investigators have proposed 
the use of in vivo phosphorus magnetic resonance spectroscopy (
31
P-MRS) to quantify 
mitochondrial oxidative function (Barbiroli et al., 1995; Lodi et al., 1997; Befroy et al., 
2009). Magnetic resonance spectroscopy offers some distinct advantages, allowing 
more physiological measurements to be obtained both at rest and following a period of 
exercise. However, a major limitation is cost and it is not widely available as a 
diagnostic resource in most clinical centres. 
1.10.7 Molecular Genetic Analysis 
The identification of the underlying genetic defect has important ramifications both for 
the proband and other family members. The patient‟s clinical presentation, in addition 
to the preliminary histochemical and biochemical findings, often allow for a targeted 
molecular approach, thereby minimizing cost and diagnostic delays. In patients with 
classical presentations of a primary mtDNA disorder, e.g. LHON and MERFF, it is 
routine practice to first screen for the most common mutations linked with these 
disorders (McFarland et al., 2002). Several methods can be used including restriction 
fragment length polymorphism (RFLP), pyrosequencing, or direct PCR-based 
sequencing. Similarly, various protocols have been developed that provide accurate 
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quantification of heteroplasmy level, such as primer extension assay (Fahy et al., 
1997), radioactive or fluorescent “last-cycle” PCR (Pyle et al., 2007). 
Whole genome mitochondrial sequencing is labour intensive and the interpretation of 
the results can pose certain difficulties. It should therefore be reserved for patients with 
a high index of suspicion for an underlying primary mtDNA defect, but found to be 
negative for the more common mutations. As mentioned previously, mtDNA is highly 
polymorphic, and if a novel variant is identified, it is sometimes not possible to be 
definitive about its pathological significance. For a mtDNA variant to be considered 
pathogenic, certain “canonical” criteria need to fulfilled (Chinnery et al., 1999b; 
McFarland et al., 2002): (i) it must not have been previously reported as a neutral 
polymorphism in human mtDNA sequence databases, (ii) it must not be detected in 
healthy controls, (iii) pathogenic mtDNA variants are usually, but not always, 
heteroplasmic, (iv) it would normally be expected to alter a highly-conserved 
nucleotide or amino-acid, and (v) it should segregate with disease status, with higher 
heteroplasmy levels detected in affected family members and in affected tissues. For 
more complex situations, e.g. a possibly pathogenic homoplasmic tRNA variant, 
confirmation of a deleterious functional consequence at the biochemical or cellular 
level is required (Tuppen et al., 2008; Horvath et al., 2009). 
It is important to note that although blood is a more easily obtained diagnostic sample, 
some mtDNA mutations, e.g. m.3243A>G, are only present at low levels in circulating 
leukocytes, with the levels often decreasing significantly with age (Pyle et al., 2007; 
Rajasimha et al., 2008). Depending on the specific clinical setting, screening of muscle 
homogenate DNA is therefore strongly recommended to avoid false negative results. 
Large-scale mtDNA rearrangements; single deletions, duplications and multiple 
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mtDNA deletions, can also be detected in homogenate muscle DNA. Southern blot 
analysis is often considered the “gold” standard when screening for these large-scale 
rearrangements, and it has the advantage of being quantitative (Taylor et al., 2000). 
MtDNA depletion can also be detected if the Southern blot is hybridised with a probe 
corresponding to a nuclear gene, such as the 18S rRNA, in addition to the 
mitochondrial probe, usually to the D-Loop region. However, Southern blot has some 
disadvantages, requiring the use of radioactive material and a relatively large starting 
quantity of genomic DNA, but more importantly, it has a detection threshold of ~ 5%. 
A second technique increasingly being used in diagnostic laboratories is long-range 
PCR, which only requires small amounts of genomic DNA. Being PCR-based, this 
assay will preferentially amplify smaller amplicons, and it will detect low levels of 
mtDNA deletions (Lightowlers et al., 1999). This can lead to some pitfalls, and it is 
important to consider the patient‟s age when only a few deletion bands are identified 
on the electrophoresis gel, in the presence of a relatively strong, wild-type band, 
corresponding to the full-length PCR product. These could represent normal ageing 
changes, as healthy individuals over the age of 60 can harbour low frequency of COX-
deficient fibres in their muscle of ~ 1% (Section 1.10.5) (Brierley et al., 1996; Brierley 
et al., 1997). A third technique, fluorescence-based real-time PCR, has been optimized 
for the identification of mtDNA deletions at the single-cell level. It allows very 
accurate quantification of both wild-type and deleted mtDNA copy number, and by 
measuring deletion levels in laser-microdissected COX-positive and COX-negative 
single cells, it is possible to determine segregation with the histochemical defect (He et 
al., 2002; Durham et al., 2007). 
Screening for an underlying nuclear defect is usually dictated by the patient‟s age, the 
clinical phenotype, and features pointing towards an underlying mtDNA maintenance 
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disorder in affected tissues. For example, in a patient presenting with a classical POLG 
phenotype characterised by CPEO, ataxia, epilepsy, and multiple mtDNA deletions, 
many diagnostic labs will initially screen for the c.1399G>A (p.A467T) and 
c.2243G>C (p.W748S) POLG1 mutations (Horvath et al., 2006; Chinnery and Zeviani, 
2008). If these nucleotide changes are not present, the entire POLG1 genomic region 
can then be sequenced, followed by other nuclear genes linked with multiple mtDNA 
deletion if still negative. The available “nuclear panel” will largely dependent on the 
diagnostic facility, and this will be influenced by cost-issues both for the laboratory 
and the patient. A primary nuclear defect is frequently not identified in patients with 
multiple mtDNA deletions, even among those with clear-cut autosomal pattern of 
inheritance. In two case series, POLG1, PEO1, and SLC25A4 were sequenced in 
patients with sporadic CPEO and multiple mtDNA deletions (Di Fonzo et al., 2003; 
Hudson et al., 2006). No PEO1 or SLC25A4 mutations were identified in these cohorts, 
and the positive hit rate for POLG1 was only 10-25%. The investigation of suspected 
nuclear mitochondrial disorder poses significant challenges, and genetic testing is still 
not widely available. Hopefully, these practical difficulties will be resolved with the 
development of cheaper, high-throughput sequencing platforms, which will also play a 
major role in accelerating the pace of discovery for as yet unidentified nuclear 
mitochondrial genes. 
1.11 Genetic Counselling 
Male carriers harbouring mtDNA point mutations can be reassured that their children 
are not at risk of inheriting their genetic defect. Female carriers will transmit the 
mutation to all their offspring, but if the mutation is heteroplasmic, it is not possible to 
reliably predict the mutational level that will be transmitted (Yu-Wai-Man et al., 2009; 
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Fraser et al., 2010). As discussed previously, significant variations in heteroplasmy 
levels can occur as a result of the mitochondrial genetic bottleneck (Section 1.3.2). The 
use of amniocentesis or chorionic villus sampling for prenatal testing is therefore 
limited in this situation, as the mutational load detected in amniocytes and chorionic 
villus cells could differ from other foetal tissues, especially those at greater risk from a 
specific mtDNA point mutation (Brown et al., 2006). For mtDNA single deletions, the 
risk of maternal transmission is relatively low, and this has been estimated at ~ 1 in 24 
births i.e. ~ 4%. There is also no evidence that increased maternal age is associated 
with an increased risk of having an affected child with a mtDNA deletion disorder 
(Chinnery et al., 2004). The risks of transmission for nuclear mitochondrial disorders 
follow the laws of Mendelian inheritance, but if a specific nuclear defect has not been 
identified, only an approximate risk can be provided based on the family history. As a 
result of the marked inter- and intra-familial phenotypic variability seen with 
mitochondrial disorders, genetic counselling for patients and their families remains a 
challenging area of practice. 
1.12 Treatments for Mitochondrial Disease 
1.12.1 Supportive Measures 
The treatment options for patients with mitochondrial genetic disorders are currently 
limited (Chinnery et al., 2006). However, there are several practical steps that can be 
taken as part of a multi-disciplinary team to improve a patient‟s quality of life, and 
minimize long-term morbidity (Yu-Wai-Man et al., 2009; Fraser et al., 2010). 
Depending on their needs, these patients should be provided with access to facilities 
such as low visual aids, physiotherapy, occupational therapy, and clinicians can help 
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with financial assistance through their local social services. It is also important to 
aggressively manage related medical problems such as diabetes and epilepsy, and 
clinicians need to be vigilant to the development of new complications such as 
cardiomyopathy and sensorineural deafness, which could be amenable to therapeutic 
intervention. Patients with mitochondrial disorders should be strongly advised not to 
smoke and to minimise their alcohol intake, not only as a general health measure, but 
smoking, and to a lesser extent excessive alcohol intake, have been linked with an 
increased risk of visual loss among LHON carriers (Kirkman et al., 2009). Patients 
with CPEO often get significant benefit from simple conservative measures such as 
ptosis props or Fresnel prisms for symptomatic ocular misalignments (Richardson et al. 
2005). In some cases, strabismus and ptosis surgery are indicated but these should be 
performed by experienced surgeons (Shorr et al., 1987; Ahn et al., 2008), because of 
the increased risk of complications such as corneal exposure secondary to  poor 
orbicularis oculi function and impaired Bell‟s phenomenon (Daut et al., 2000). 
1.12.2 Disease-Modifying Treatments 
On the basis of limited, mostly anecdotal evidence, various combinations of  
pharmacological agents  have been used to treat patients with mitochondrial disorders 
including multi-vitamin supplements, CoQ10 and its derivatives, and putative free 
radical scavengers (Horvath et al., 2008; Tarnopolsky, 2008; Schon et al., 2010). There 
is relatively more clinical data on the use of CoQ10, which has shown a clear benefit for 
patients with primary CoQ10 deficiency (Mancuso et al., 2010). In one randomised, 
double-blind, crossover study of 16 patients with mitochondrial cytopathies, a 
combination of CoQ10 with creatine monohydrate and α-lipoic acid, reduced the levels 
of resting plasma lactate and oxidative stress markers (Rodriguez et al., 2007). 
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Idebenone is a synthetic analogue of CoQ10, and it is currently being investigated as a 
treatment option for neurodegenerative disorders such as Friedreich ataxia (FRDA) and 
LHON. Idebenone is able to operate under low oxygen tension and it is thought to have 
antioxidant properties, in addition to optimising ATP production by the respiratory 
chain complexes (Tonon and Lodi, 2008; Sacconi et al., 2010). Initial reports of 
idebenone therapy in FRDA showed promising results with  an improvement in both 
cardiac and neurological status (Rustin et al., 2004; Di Prospero et al., 2007). However, 
preliminary data released from two recently completed randomised controlled trials 
have proven rather disappointing, with no significant difference in primary cardiac and 
neurological endpoints between the idebenone treated and placebo FRDA groups. 
(http://www.santhera.com/index.php?mid=6&vid=&lang=en, Accessed 31
st
 of August 
2010). In a retrospective study of 28 affected LHON patients, half of whom received a 
combination of idebenone, vitamin B2, and vitamin C for at least one year, the  treated 
group showed a faster rate of visual recovery (Mashima et al., 2000). However, in a 
more recent report, megadoses of idebenone, vitamin C, and riboflavin did not prevent 
second eye involvement in two m.11778G>A LHON carriers treated after the onset of 
unilateral visual loss, and both patients showed no improvement in visual function 
(Barnils et al., 2007). The benefits of idebenone in LHON remains unclear, but as it is 
a safe drug, it is often recommended by clinicians or self-prescribed by patients. A 
randomised controlled trial of idebenone in LHON has recently been completed, and 
the preliminary results suggest a beneficial effect, especially among patients with 
recent disease onset, and relatively good visual acuity in the second eye to be affected. 
(http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=201006&
newsid=1424223&newslang=en, Accessed 31
st
 of August 2010). 
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The pathology seen in MNGIE is secondary to imbalances in the intramitochondrial 
dNTP pools, and the toxic accumulations of thymidine and deoxyuridine. Allogenic 
haematopoietic stem cell transplantation (HSCT) has shown some evidence of benefit 
in a small group of patients, with a partial restoration of buffy coat thymidine 
phosphorylase activity, and the lowering of plasma nucleosides levels (Hirano et al., 
2006; Halter et al., 2010). However, this procedure entails significant risks and 
additional work is needed to determine whether correcting the biochemical 
abnormalities in blood will improve the prognosis for patients with MNGIE (Chinnery 
and Vissing, 2006). 
1.12.3 Gene Therapy 
MtDNA mutations are often present in the heteroplasmic state and most of them show 
a threshold effect, with a biochemical defect only becoming apparent above a 
mutational load of 60-80% (Section 1.2.5). Theoretically, by lowering the level of the 
pathogenic mutation to below this biochemical threshold, one could expect a functional 
improvement in tissue function. This forms the basis of “gene shifting” as a treatment 
modality for mitochondrial diseases, and different approaches have been adopted by 
research groups worldwide (Taylor et al., 1997a; Horvath et al., 2008; Fraser et al., 
2010). A promising option is exercise training, which not only improved muscle 
strength and the quality of life for patients with single mtDNA deletions, but also 
decreased the number of COX-negative fibres in their muscle biopsies (Taivassalo et 
al., 2006; Taivassalo et al., 2007; Murphy et al., 2008). The mechanism is likely to 
involve the activation and replication of muscle satellite cells in response to myofibre 
damage. These myogenic precursors are thought to contain lower levels of the mutant 
mtDNA species (Clark et al., 1997), and as they differentiate into myocytes and merge 
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with existing myofibre segments, the overall mutational burden is reduced (Zeviani, 
2008). Another technique for gene shifting is the use of mutation-specific restriction 
endonucleases, which successfully reduced the level of the m.8993T>G mutation in 
cybrid cell lines (Tanaka et al., 2002). Peptide nucleic acids (PNAs) have also been 
shown to be effective in inhibiting the replication of mutant, but not wild-type, mtDNA 
in vitro (Taylor et al., 1997b). 
Classical gene therapy is proving very challenging for primary mitochondrial 
disorders, because the tools required for successful gene transfer into the mitochondrial 
genome is still not available (DiMauro and Mancuso, 2007; Kyriakouli et al., 2008; 
DiMauro and Rustin, 2009). The mitochondrial inner membrane represents a 
significant physical barrier that needs to be overcome, and given the large number of 
mitochondria per cell, a highly efficient vector will be required to achieve an adequate 
level of transfection. To bypass these difficulties, allotopic strategies have been 
developed where the gene of interest is transfected into the nuclear genome, usually by 
an adenovirus-associated virus (AAV) vector (Manfredi et al., 2002; Qi et al., 2007a). 
The protein product has a mitochondrial targeting sequence and as result, it gets 
imported into the mitochondrial compartment, either replacing the missing protein or 
complementing the dysfunctional mutant protein (See also Section 1.13.2). 
1.12.4 Preventing Transmission 
Following successful fertilisation, two distinct structures can be observed within the 
fertilised oocyte, known as the male and female pronuclei (Brown et al., 2006). Given 
the lack of treatment for mitochondrial disorders, pronuclear transfer is currently being 
investigated as a method to prevent the transmission of mtDNA mutations in human 
embryos (Tachibana et al., 2009; Craven et al., 2010). This strategy involves the 
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replacement of the entire mitochondrial population, by transferring karyoplast 
containing the pronuclei from a donor zygote to an enucleated recipient zygote. In a 
landmark study using abnormally fertilized human zygotes, Craven and colleagues 
have shown that pronuclear transfer resulted in minimal carry-over of donor zygote 
mtDNA, and it was compatible with successful progression to the blastocyst stage 
(Craven et al., 2010). 
1.13 Animal Models of Mitochondrial Disease 
1.13.1 Autosomal Dominant Optic Atrophy 
Two DOA mouse models have recently been developed which harbour pathogenic 
mutations in exon 8 (c.1051C>T) and intron 10 (c.1065+5g>a) of the Opa1 gene 
(Alavi et al., 2007; Davies et al., 2007). These mutations are truncative in nature and  
they result in a 50% reduction in the overall expression of the Opa1 protein. In both 
models, homozygous mutant mice (Opa1-/-) died in utero during embryogenesis, 
highlighting the central role played by the Opa1 protein in early development. 
Heterozygous Opa1+/- mice faithfully replicated the human phenotype exhibiting a 
slowly progressive optic neuropathy and demonstrating objective reduction in visual 
function on psychophysical testing. Visual evoked potential (VEP) measurements 
showed significantly reduced amplitudes, but no change in latencies, supporting an 
ascending progress of degeneration from the soma towards the axon (Heiduschka et al., 
2010). Histological and retrograde labelling experiments confirmed a gradual loss of 
RGCs and an associated thinning of the retinal nerve fibre layer. The surviving optic 
nerve axons had an abnormal morphology with swelling, distorted shapes, irregular 
areas of demyelination and myelin aggregates. These features of optic nerve 
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degeneration were seen as early as nine months, but they were much more visible by 
24 months. An increased number of autophagosomes was also noted in the RGC layer 
of heterozygous Opa1+/- mice at these later time points, which is probably due the 
accumulation of dysfunctional mitochondria (White et al., 2009). Mitochondria within 
these axons showed disorganized cristae structures on transmission electron 
microscopy and cultured fibroblasts showed increased fragmentation of their 
mitochondrial network. A third Opa1 mouse model is currently being characterised 
harbouring a heterozygous c.2708-2711delTTAG mutation in exon27. Heterozygous 
mutant mice are showing signs of optic nerve degeneration from the age of 6 months, 
with subnormal VEPs, and abnormal mitochondrial distribution, especially in the 
lamina cribosa region (Dr Guy Lenaers, personal communication). All these Opa1 
mouse models only manifest pure optic atrophy, and it will be important to create a 
DOA+ mouse model in order to dissect the mechanisms which contribute to multi-
system involvement. 
The majority of families with DOA harbour pathogenic OPA1 mutations, but OPA3 
mutations have also been described in two French families with a dominantly inherited 
phenotype characterised by optic atrophy and early-onset cataracts (Reynier et al., 
2004). Interestingly, OPA3 mutations were originally described in Iraqi Jewish patients 
with Costeff‟s syndrome, an autosomal recessive, relentlessly progressive 
neurodegenerative disorder associated with 3-methylglutaconic aciduria (Anikster et 
al., 2001). Davies and colleagues have recently reported an Opa3 mouse model 
carrying a c.365T>C (p.L122P) mutation (Davies et al., 2008). Heterozygous Opa3+/- 
mice were not compromised, whereas homozygous Opa3-/- mice developed multi-
system organ failure with cachexia, dilated cardiomyopathy, extrapyramidal features, 
and a reduced lifespan of less than four months. These mice had severely impaired 
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visual function, and although all the retinal layers were affected, cell loss was much 
more prominent within the RGC layer, further reinforcing the selective vulnerability of 
this specific cell type. 
1.13.2 Leber Hereditary Optic Neuropathy 
There is still no animal model where the primary LHON mutations have been 
successfully introduced into the mitochondrial genome. In spite of these technical 
difficulties, four experimental techniques have been developed which can replicate the 
optic nerve degeneration seen in LHON: (i) intravitreal injection of a respiratory chain 
poison such as rotenone (Zhang et al., 2002), (ii) stereotactic injection of biodegradable 
rotenone-loaded microspheres into the optical layer of the superior colliculus (Marella 
et al., 2010), (iii) downregulation of nuclear-encoded complex I subunits (e.g. 
NFUFA1) with specific mRNA-degrading ribozymes (Qi et al., 2003), and (iv) 
allotopic expression of mutant subunits (e.g. MTND4) which are then imported into 
the mitochondria (Qi et al., 2007b; Ellouze et al., 2008). These disease models will be 
indispensable when testing the feasibility of gene therapy in LHON, and different 
strategies are currently being pursued. It has been shown both in vitro and in vivo that 
the loss of RGCs could be dramatically reduced by transfecting them with an AAV 
vector containing the human SOD2 gene (Qi et al., 2004; Qi et al., 2007a). The 
increased expression of the superoxide dismutase enzyme is thought to improve RGC 
survival by minimizing free radical damage, and decreasing the cell‟s susceptiblity to 
undergo apoptosis. Allotopic rescue, with the replacement of the defective 
mitochondrial complex subunit, is another attractive option for gene therapy in LHON 
(Section 1.12.3). Proof-of-principle for this approach has already been demonstrated in 
a rat model expressing a defective ND4 gene containing the m.11778A>G primary 
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LHON mutation (Ellouze et al., 2008). The loss of visual function in these rats was 
reversed by transfecting RGCs with the wild-type ND4 gene, using an in vivo 
electroporation technique instead of an AAV vector. The transgene became stably 
integrated within the nuclear genome and the level of expression achieved was 
sufficient for successful RGC neuroprotection. These early studies of allotopic rescue 
in LHON are promising, but the results need to be replicated in larger animals, and 
long-term safety data is essential before human clinical trials can be contemplated 
(Friedmann, 2000; Miller, 2008). These issues of safety and efficacy are especially 
relevant given the significant concerns that have been raised recently about the 
limitations of allotropic rescue in the treatment of primary mtDNA disorders (Perales-
Clemente et al., 2010). As yet, there is no conclusive experimental evidence that 
allotopically-expressed mitochondrial subunits can be properly integrated into fully-
assembled OXPHOS complexes. Mitochondrially-encoded complex I subunits are also 
highly hydrophobic and if a proportion of these polypeptides are not imported, they 
could have deleterious consequences by physically aggregating into the cytosol or 
triggering an inappropriate immune response. 
1.13.3 Chronic Progressive External Ophthalmoplegia 
The development of a faithful mouse model with the classical ocular features of CPEO 
has proven difficult to achieve (Tyynismaa and Suomalainen, 2009; Wallace and Fan, 
2009). In an Ant1 mouse model, extraocular muscles (EOMs) from homozygous 
mutant Ant1-/-  mice showed pathological mitochondrial changes which were similar 
to those seen in skeletal muscle from patients with CPEO (Yin et al., 2005). EOM 
fibres had an increase in intracellular mitochondrial content with characteristic 
subsarcolemmal accumulation of mitochondria. However, none of the Ant1-/- mice 
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developed marked ptosis or restriction in ocular motility (Yin et al., 2005). Two 
transgenic Twinkle mice colonies have also been created harbouring dominant 
mutations previously shown to be pathogenic in humans: dup352-364 and A359T 
(Tyynismaa et al., 2005). COX-deficiency was observed in skeletal muscle and distinct 
brain regions of heterozygous Twinkle
dup
 and Twinkle
AT
 mice, with Southern blot and 
long PCR confirming the accumulation of multiple mtDNA deletions in these tissues. 
EOMs from these mice were not studied, but similar to the Ant1 mice, the Twinkle 
mice did not develop features suggestive of CPEO. It is not entirely clear why these 
mouse models fail to replicate the prominent ocular phenotype seen in patients 
harbouring SLC25A4 and PEO1 mutations, despite clear histological and molecular 
evidence of mitochondrial dysfunction in post-mitotic tissues. Inter-species differences 
in EOM physiology such as fatigue resistance could be important, but there also 
technical limitations, which could have resulted in subtle deficits in EOM function 
being missed. It will be very interesting to document the EOM features present in a 
future DOA+ mouse model, and determine whether CPEO eventually develops during 
the course of the disease process. 
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The aim of my PhD project was to further our understanding of mitochondrial 
disorders with ocular manifestations, both from the clinical and molecular genetic 
perspectives. The published work presented in this thesis are focused on the following 
main research areas: 
2.1 Autosomal Dominant Optic Atrophy 
In the initial phase of this project, I set about defining the epidemiology and natural 
history of DOA in a defined geographical region encompassing the North of England. 
A detailed neuro-ophthalmological assessment was performed on all patients, with the 
collection of additional data such as retinal nerve fibre layer thickness with optical 
coherence tomography (OCT), and in vivo mitochondrial oxidative function with 
phosphorus magnetic resonance spectroscopy (
31
P-MRS). A relatively high proportion 
of affected OPA1 carriers developed DOA+ features, and in a subsequent multi-centre 
study, I collected a large dataset which confirmed the expanding phenotypic spectrum 
linked with OPA1 disease. In collaboration with research groups at the University of 
Tübingen (Germany) and Emory University (USA), we further studied the frequency 
of OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies. 
During the course of these clinical studies , it became evident that the same OPA1 
mutation could cause both pure and syndromal forms of DOA. In order to explore the 
basic disease mechanisms that influenced the development of these additional 
neuromuscular features, I investigated the mitochondrial changes present in tissues 
from two Opa1 mouse models, and patients with both pure DOA and DOA+ 
phenotypes. 
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2.2 Leber Hereditary Optic Neuropathy 
LHON carries a poor visual prognosis and in a multi-centre study using the VF-14 
questionnaire, the quality of life of a large group of affected and unaffected LHON 
carriers was formally assessed. The marked gender bias and incomplete penetrance in 
LHON is still not fully understood, and using the same patient cohort, the contribution 
of possible environmental triggers was studied further. 
2.3 Chronic Progressive External Ophthalmoplegia 
CPEO is a frequent manifestation of mitochondrial genetic disorders, being observed 
in at least a third of all affected patients. Interestingly, it often develops in isolation, 
and even when other neurological features are present, the severity of ptosis and 
ophthalmoplegia often predominates. In order to investigate this selective involvement, 
we first documented the mitochondrial changes seen in EOMs during normal ageing, 
relating our findings to those seen in skeletal muscle. We then performed a 
comprehensive histological and molecular genetic study comparing the pathological 
features seen in EOM and skeletal muscle samples from patients with CPEO. 
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